Polymer excipients for drug delivery applications
Multiblock poly(amino acid) copolymers self-assemble into micelles to enhance the solubility of hydrophobic drugs, addressing the limitations of existing excipients and providing a cost-effective, safer alternative for solubilizing a broad range of hydrophobic APIs.
Patent Information
- Application Number
- JP2024154941
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-28
AI Technical Summary
Existing polymeric excipients struggle to adequately solubilize a wide range of hydrophobic APIs, including 'grease balls' and 'brick dust', leading to the need for costly and potentially immunogenic PEG-containing alternatives or chemically modified APIs, which are not well-studied for safety and efficacy.
Development of multiblock poly(amino acid) copolymers with hydrophilic poly(sarcosine) and hydrophobic poly(amino acid) blocks that spontaneously self-assemble into micelles, encapsulating hydrophobic molecules to enhance their solubility in aqueous solutions, eliminating the need for solubilizing agents like Cremophor EL.
The multiblock copolymers effectively increase the solubility of hydrophobic drugs, reducing infusion-related side effects and production costs while maintaining safety and efficacy, offering a versatile solution for various hydrophobic APIs.
Smart Images

Figure 2024166296000031 
Figure 2024166296000001 
Figure 2024166296000002
Abstract
Description
[Technical field]
[0001] Field of Disclosure The present disclosure is directed to the field of polymer chemistry, and more particularly, to multi-block poly(amino acid) copolymers and uses thereof. [Background technology]
[0002] Background of the Disclosure Polymeric excipients are commonly utilized in the formulation of pharma- ceutically active ingredients (APIs). These polymers are used to aid in tablet dissolution, provide binders, or modify the viscosity of oral formulations. In some cases, polymeric excipients are used to increase the aqueous solubility of hydrophobic APIs. Poly(ethylene glycol) (PEG), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PGLA), and cyclodextrins (CD) are non-limiting examples of polymeric excipients routinely used in pharmaceutical development to improve the solubility of hydrophobic APIs. However, when these standard excipients do not adequately solubilize the hydrophobic drug, few options remain. In such cases, the API can be chemically modified to increase its aqueous solubility (e.g., creating a new API, such as a prodrug, or polymer drug conjugate), the compound can be rejected, or new non-standard excipients can be developed. Often, these new excipients are custom designed for the API of interest. This is evidenced by the large number of drug delivery technologies developed by academic research groups to solubilize specific APIs.Unless a novel drug product progresses to the commercial stage, the public knows very little about the synthesis, toxicity, and usefulness of such solubility-enhancing excipients.
[0003] Thus, without wishing to be bound by any particular theory, it would be desirable to develop polymeric excipients with broad utility for solubilizing a wide range of hydrophobic APIs. Such excipients would be required to encapsulate amorphous, high logP compounds (colloquially referred to as "grease balls"), as well as highly crystalline hydrophobic APIs (colloquially referred to as "brick dust").
[0004] Polymeric micelles provide a method for solubilizing hydrophobic compounds. They are formed by thermodynamic self-assembly of amphiphilic block copolymers into core-shell type structures (see Yu, K. et al. Macromolecules 1996, 29(19), 6359; Roesler, A. et al. Adv. Drug Deliv. Rev. 2012, 64, 270). For polymeric micelles in aqueous solution, the hydrophilic block of the polymer forms the corona of the micelle, while the hydrophobic block forms the core. When micelle formation is performed in the presence of additional hydrophobic molecules (e.g., hydrophobic drugs), the hydrophobic compound spontaneously orients itself to the hydrophobic core of the polymeric micelles and is sequestered. The hydrophobic drug is made water-soluble by the hydrophilic corona of the polymeric micelles. It is important to note that in this particular application, the drug is physically entrapped and not chemically bound to the polymer chains.
[0005] A large number of amphiphilic block copolymers for drug delivery applications have been reported in the literature (see Kedar, U. et al. Nanomedicine 2010, 6(6), 714; Ahmad, Z. et al. RSC Adv. 2014, 33, 17028; Kataoka, K. et al. Adv. Drug Delivery Rev. 2001, 47(1), 113). PEG-PGLA, PEG-PLA, PEG-poly(amino acids), poly(acrylate)-block-poly(methacrylate) and their derivatives are all common polymers that have been investigated for polymeric micelle-based drug delivery applications. Most of these polymers include the use of PEG as the hydrophilic component. PEG is widely regarded as a non-toxic, non-immunogenic compound and has been used for decades in food, cosmetic and pharmaceutical products. However, recent studies have begun to show that there may be immunogenic reactions to PEG-containing materials, especially for intravenous products (see Garay, R. et al., Expert Opin. Drug Delivery, 2012, 1319-1323; Yang, Q. et al., Anal. Chem. 2016, 88(23), 11804-11812; Wenande, E. et al., Clin. Exp. Allergy, 2016, 46(7), 907-922.; Webster, R. Drug Metab. Dispos, 2007, 35(1), 9-16). Such PEG-containing pharmaceutical products may also cause infusion-related reactions (see Browne, EK et al. J. Pediatr Oncolo. Nurs. 2018, 35(2), 103).Furthermore, the production of high-purity pharma- ceutically acceptable PEG derivatives involves the extremely hazardous polymerization of ethylene oxide, and even trace impurities in the product can significantly affect its application (see Vojkovsky, T. et al. Polymer, 2016, 105, 72-78; Sill, K. et al. Biomacromolecules 2017, 18(6), 1874-1884). This makes the use of PEG-containing pharmaceuticals expensive and therefore cost-prohibitive for certain applications. Other polymers commonly used for drug delivery applications are based on acrylate or other vinyl polymer chemistry. Such polymers are prepared by anionic or radical polymerization of vinyl monomers. In many cases, these monomers, such as butyl acrylate, are potent sensitizers. Furthermore, because the backbone of these polymers is composed exclusively of carbon-carbon bonds, these polymers are biocompatible but do not degrade in vivo. [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Garay, R. et al., Expert Opin. Drug Delivery (2012) 1319-1323 [Non-Patent Document 2] Yang, Q. et al., Anal. Chem. (2016) 88(23) 11804-11812 [Non-Patent Document 3] Wenande, E. et al., Clin. Exp. Allergy (2016) 46(7) 907-922 Summary of the Invention [Means for solving the problem]
[0007] A brief summary of the disclosure The present disclosure is directed to multi-block copolymers comprising a hydrophilic poly(sarcosine) block and a hydrophobic poly(amino acid) block comprising a mixture of D- and L-amino acids. The multi-block copolymers can be synthesized by polymerization of the corresponding amino acid N-carboxyanhydrides. As described herein, the multi-block copolymers are useful for encapsulating hydrophobic molecules, thereby increasing the solubility of the molecules in aqueous solutions. The compositions of the present disclosure include drug products comprising the multi-block copolymers and hydrophobic drugs. Such compositions increase the solubility of the hydrophobic drugs in diluents commonly used for parenteral administration. Also provided herein are methods for preparing the compositions or unit dose forms described herein. [Brief description of the drawings]
[0008] [Figure 1] Pharmacokinetic profile of TYN-21 in rats versus Abraxane at an equivalent paclitaxel dose of 5.0 mg / kg. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE DISCLOSURE 1. General Description: As described herein, the present disclosure is directed to multi-block poly(amino acid) copolymers. The first block is a hydrophilic poly(sarcosine) block and the second block is a hydrophobic poly(amino acid) block comprising a mixture of D- and L-amino acids. Such copolymers spontaneously self-assemble into micellar structures in aqueous solution, with the hydrophilic poly(sarcosine) block forming the corona and the hydrophobic poly(amino acid) block forming the core of the micelle. During such assembly, if a hydrophobic molecule (e.g., an API, compound, drug or pharmaceutical active agent) is present, the molecule can be sequestered in the hydrophobic portion of the micelle. This has the effect of increasing the solubility of the hydrophobic molecule in aqueous solution. The amide backbone of the poly(sarcosine) block can adopt both cis and trans configurations, while the poly(amino acid) block comprising a mixture of both D- and L-amino acids hinders the formation of secondary and tertiary structures. Without wishing to be bound by any particular theory, it is believed that these two properties combine to increase the rotational freedom, thereby allowing the multiblock poly(amino acid) copolymer to adopt a multitude of conformations, which encourages the associated hydrophobic molecule to find the lowest possible energy state. When the hydrophobic molecule is a hydrophobic drug, it will be appreciated that the compositions of the present disclosure are useful for parenteral administration using common aqueous diluents (e.g., saline or D5W) without the need for additional solubilizing agents, such as Cremophor® EL (polyoxyethylated castor oil). Those skilled in the art will recognize the advantage of not needing Cremophor EL, which is known to cause several injection-related side effects, including bronchospasm, hypotension, peripheral neuropathy, and anaphylactic reactions. These side effects may be reduced by the use of H, to reduce hypersensitivity reactions to Cremophor EL-based paclitaxel formulations. 1 and H 2Premedication with antagonists and longer infusion times are required. (See Authier, N. et al., Neurotox. Res. 2001, 3, 301-306; Gelderblom, H. et al., Eur. J. Cancer 2001, 37, 1590-1598; Brat, D. et al., Pharmacology Exp. Ther.1992, 261, 803-810; Windebank, AJ et al., J. Pharmacology Exp. Ther.1994, 268, 1051-1056; Van Zuylen, L. et al., Investigational New Drugs, 2001, 19, 125-141). Cremophor EL also extracts DEHP (di(2-ethylhexyl)phthalate), a plasticizer derived from polyvinyl chloride (PVC) materials, making it incompatible with standard intravenous tubing. Furthermore, drugs (e.g., paclitaxel) formulated with Cremophor EL can become trapped in Cremophor micelles, which results in nonlinear pharmacokinetics (see Sparreboom, A. et al., Cancer Res, 1999, 59, 1454-1457).
[0010] In some embodiments, the poly(amino acid) copolymers of the present disclosure can be prepared by polymerization of the corresponding amino acid N-carboxyanhydrides (NCAs). The multi-block copolymers of the present disclosure can be prepared by sequential polymerization of a sarcosine NCA followed by a mixture of D- and L-amino acid NCAs. In some embodiments, the polymerization is carried out in a single solvent and the final copolymer is isolated by precipitation with a single anti-solvent. Solvents and reagents are used "as received" and no further steps are taken to purify or exclude air and / or moisture (e.g., Schlenk technique) as commonly used for NCA polymerization (see Aliferis, T. et al. Biomacromolecules 2004, 5(5), 1653.; Deming, TJ et al. Nature 1997, 390(6658), 386; Kricheldorf, HR α-Amino acid-N-carboxy-anhydrides and related heterocycles: syntheses, properties, peptide synthesis, polymerization, Berlin, Springer-Verlag, 2011). This will be appreciated, among other things, as it minimizes the costs associated with preparing poly(amino acid) copolymers on a commercial scale under Good Manufacturing Practice (GMP) guidance, since only a minimal amount of solvent needs to be procured and quantified during release testing.
[0011] 2.Definition: Below are definitions of various terms used herein to explain this disclosure, and are further exemplified by the embodiments, subembodiments, and species disclosed herein. These definitions apply to the terms as they are used throughout this specification, unless otherwise indicated in specific instances, either individually or as part of a larger group.
[0012] For purposes of this disclosure, chemical elements are defined as defined in the CRC Handbook of Chemistry and Physics, 100 th The elements are identified according to the Periodic Table of the Elements, Ed. Further, general principles of organic chemistry are described in Sorrell, T. Organic Chemistry, 2001, the entire contents of which are incorporated herein by reference. nd Ed., Sausalito, University Science Books, 2005; and Smith, MB March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7 th Ed., New York, J. John Wiley & Sons, 2001.
[0013] The term "about," when referring to a measurable value, such as an amount, time period, or the like, refers to a variation of ±20%, or in some cases ±10%, or in some cases ±5%, or in some cases ±2%, or in some cases ±1%, or in some cases ±0.1% of the specified value, where such variations are appropriate for the purposes of this disclosure.
[0014] The terms "TFS-1" and "poly(sarcosine) 175 -block-poly(d-leucine) 35 -co-Tyrosine 25 )," "PSar 175 -P(dLeu 35 / Tyr 25 )," "Poly[Sar 175 ]-block-poly-[D-Leu 35 -co-L-Tyr 25 ]" and the following structure: [ka] It is understood that copolymers having the following structures all represent the same compound and can be used interchangeably.
[0015] The terms "TFS-2" and "poly(sarcosine) 175 -block-poly(d-leucine) 30 -co-Tyrosine 20 )," "PSar 175 -P(dLeu 30 / Tyr 20 )," "Poly[Sar 175 ]-block-poly-[D-Leu 30 -co-L-Tyr 20 ]" and the following structure: [ka] It is understood that copolymers having the following structures all represent the same compound and can be used interchangeably.
[0016] The terms "TFS-3" and "poly(sarcosine) 235 -block-poly(d-phenylalanine) 10 -co-Tyrosine 30 )," "PSar 235 -P(dPhe 10 / Tyr 30 )," "Poly[Sar 235 ]-block-poly-[D-Phe 10 -co-L-Tyr 30 ]" and the following structure: [ka] It is understood that copolymers having the following structures all represent the same compound and can be used interchangeably.
[0017] As used herein, the term "block copolymer" refers to a polymer that includes two or more poly(amino acid) moieties. As described herein, one or more of the amino acid blocks may be "mixed blocks", meaning that these blocks may contain a mixture of amino acid monomers, thereby resulting in the block copolymers of the present disclosure. Those skilled in the art will recognize that the monomer repeat units are defined by the parentheses shown around the repeating monomer units. The number (or letter representing a numerical range) to the right of the parentheses represents the number of monomer units present in the polymer chain. In cases where only one type of monomer represents a block (e.g., a homopolymer), the block is simply represented by parentheses. In the case of a mixed block, the monomers comprise a single continuous block. It will be understood that the brackets define a portion or block. For example, if a block can consist of four individual monomers, each is defined by its own individual set of parentheses and the number of repeat units present. All four sets of parentheses are enclosed in a single set of square brackets, meaning that all four of these monomers come together in a random or near-random order, including a mixed block. For clarity, a randomly mixed block of [BCADDCBADABCDABC] is represented as [(A) 4 (B) 4 (C) 4 (D) 4 ] is an abbreviation.
[0018] As used herein, the above monomer repeat units are numbers that represent the number average of the monomer units that comprise the polymer chain. For example, (A) 10A polymer represented by corresponds to a polymer consisting of 10 "A" monomer units linked together. One skilled in the art will recognize that the number 10 in this case represents a distribution of numbers with an average of 10. The breadth of this distribution is represented by the polydispersity index (PDI). A PDI of 1.0 represents a polymer (e.g., a protein) in which each chain length is exactly the same. A PDI of 2.0 represents a polymer with a Gaussian distribution of chain lengths. Polymers of the present disclosure typically have a PDI of less than 1.20.
[0019] As used herein, "multiblock copolymer" or "copolymer" refers to a polymer that contains two or more poly(amino acid) blocks.
[0020] As used herein, the term "poly(amino acid)" or "amino acid block" refers to a chain of covalently linked amino acids, each monomer being an amino acid unit. Such amino acid units include natural and unnatural amino acids. Such poly(amino acids) include those with suitably protected functional groups. For example, the amino acid monomers may have hydroxyl or amino moieties, which are optionally protected by hydroxyl or amine protecting groups, as appropriate. As used herein, an amino acid block includes one or more monomers, or a set of two or more monomers. In certain embodiments, an amino acid block includes one or more monomers such that the entire block is hydrophilic or hydrophobic. In still other embodiments, the amino acid blocks of the present disclosure include random amino acid blocks, including blocks that include a mixture of amino acid residues. Exemplary poly(amino acids) include poly(D-leucine-co-tyrosine) and poly(D-phenylalanine-co-tyrosine).
[0021] As used herein, the term "D,L-mixed poly(amino acid) block" refers to a poly(amino acid) block in which the poly(amino acids) are composed of a mixture of amino acids in both the D- and L-configuration. In certain embodiments, the D,L-mixed poly(amino acid) block is hydrophobic. In other embodiments, the D,L-mixed poly(amino acid) block is composed of a mixture of hydrophobic amino acid side groups in the D-configuration and hydrophilic amino acids in the L-configuration, such that the entire poly(amino acid) block is hydrophobic.
[0022] As used herein, the phrase "natural amino acid" refers to any amino acid that naturally occurs in proteins and naturally occurs in nature. Such natural amino acids include non-polar or hydrophobic amino acids, namely glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan and proline. Cysteine is sometimes classified as non-polar or hydrophobic, and sometimes as polar. Natural amino acids also include polar or hydrophilic amino acids, such as tyrosine, serine, threonine, aspartic acid (also known as aspartate when charged), glutamic acid (also known as glutamate when charged), asparagine and glutamine. Certain polar or hydrophilic amino acids have a charged side chain. Such charged amino acids include lysine, arginine and histidine. Those skilled in the art recognize that the protection of the side chain of a polar or hydrophilic amino acid can make the amino acid non-polar. For example, the hydroxyl group of a suitably protected tyrosine can be rendered non-polar and hydrophobic by protecting the hydroxyl group. For clarity, sarcosine is an amino acid that naturally occurs in nature.
[0023] As used herein, the phrase "side chain group of a natural amino acid" refers to the side chain group of any natural amino acid, as defined herein. For clarity, the side chain group -CH 3represents the side chain group of the naturally occurring amino acid alanine.
[0024] As used herein, the phrase "unnatural amino acid" refers to any amino acid that is not included in the list of amino acids that are naturally occurring in proteins and naturally occurring in nature, as described above. Unnatural amino acids also include homoserine, ornithine and thyroxine. Exemplary unnatural amino acids include β-trityl-asparagine, β-benzyl-aspartic acid, S-benzyl-cysteine, cyclohexylglycine, γ-benzyl-glutamic acid, γ-tert-butyl-glutamic acid, ε-trifluoroacetyl-lysine, ε-Boc-lysine, ε-benzyl-lysine, β-benzyl-serine, O-acetyl-tyrosine. Other unnatural amino acids include modified amino acids, including those that are N-alkylated, cyclized, phosphorylated, acetylated, amidated, azido, labeled, etc.
[0025] As used herein, the phrase "side chain group of a non-natural amino acid" refers to the side chain group of any non-natural amino acid, as defined herein. For clarity, the side chain group -(CH 2 ) 2 CO 2 CH 2 C 6 H 5 represents the side chain group of the unnatural amino acid γ-benzyl-glutamic acid.
[0026] As used herein, the term "amino acid" is understood to be a general term and includes both natural and unnatural amino acids. The term "D-amino acid" is understood to refer to natural or unnatural amino acids having a D-configuration. The term "L-amino acid" is understood to refer to natural or unnatural amino acids having an L-configuration.
[0027] As used herein, the term "tacticity" refers to the stereochemistry of a poly(amino acid) block. A poly(amino acid) block composed of a single stereoisomer (e.g., all L-isomers) is called "isotactic". A poly(amino acid) composed of random incorporation of D- and L-amino acid monomers is called an "atactic" polymer. A poly(amino acid) with alternating stereochemistry (e.g., ...DLDLDL...) is called a "syndiotactic" polymer. Polymer tacticity is described in Odian, G. Principles of Polymerization, 4th Ed., 1999, 1 ... th Ed., New York, John Wiley & Sons, 1991.
[0028] As used herein, the phrase "living polymer chain-end" refers to an end resulting from a polymerization reaction that retains the ability to further react with additional monomer or polymerization terminator.
[0029] As used herein, the term "termination" refers to the attachment of an end group to a polymer chain-end by reacting a living polymer with an appropriate compound. Alternatively, the term "termination" can refer to the attachment of an end group to an amine or hydroxyl end of a polymer chain, or derivatives thereof.
[0030] As used herein, the term "polymerization terminator" is used interchangeably with the term "polymerization terminating agent" and refers to a compound that reacts with a living polymer chain-end to give a polymer having a terminal group. Alternatively, the term "polymerization terminator" may refer to a compound that reacts with an amine or hydroxyl end of a polymer chain, or derivatives thereof, to give a polymer having a terminal group.
[0031] As used herein, the term "polymerization initiator" refers to a compound that reacts with a desired monomer, or a compound whose anionic or free base form reacts with such monomer, in a manner that results in polymerization of such monomer. In certain embodiments, the polymerization initiator is an amine.
[0032] The term "aliphatic" or "aliphatic group," as used herein, refers to a hydrocarbon moiety that can be linear (i.e., unbranched), branched, or cyclic (including fused, bridged, and spiro-fused polycyclic), and may be fully saturated or may contain one or more units of unsaturation, but is not aromatic. Unless otherwise specified, an aliphatic group contains 1-20 carbon atoms. In some embodiments, an aliphatic group contains 1-10 carbon atoms. In other embodiments, an aliphatic group contains 1-8 carbon atoms. In still other embodiments, an aliphatic group contains 1-6 carbon atoms, and in still other embodiments, an aliphatic group contains 1-4 carbon atoms. The number of carbon atoms present in an aliphatic group may also be specified prior to reciting said aliphatic group. For example, the term (C1-C6)aliphatic refers to an aliphatic group, as defined herein, containing 1-6 carbon atoms. The present disclosure is specifically intended to include each and every individual subcombination of the members of such ranges. In particular, the term (C1-C6) aliphatic is intended to include C1 aliphatic (e.g., methyl), C2 aliphatic (e.g., ethyl, ethylene or ethylyne), C3 aliphatic, C4 aliphatic, C5 aliphatic and C6 aliphatic. Aliphatic groups include, but are not limited to, linear or branched alkyl, alkenyl and alkynyl groups, as well as hybrids thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0033] The term "heteroatom" refers to one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon. It includes any oxidized form of nitrogen, sulfur, phosphorus, or silicon, the quaternized form of any basic nitrogen, or =N- in 3,4-dihydro-2H-pyrrolyl, -NH- in pyrrolidinyl, or =N(R) in N-substituted pyrrolidinyl. † )-, including substitutable nitrogens of heterocyclic rings.
[0034] The term "unsaturated," as used herein, means that a moiety has one or more units of unsaturation.
[0035] The term "aryl" used alone or as part of a larger moiety such as "aralkyl", "aralkoxy" or "aryloxyalkyl" refers to monocyclic, bicyclic and tricyclic ring systems having a total of 5 to 14 ring members, in which at least one ring in these systems is aromatic, and in which each ring in these systems contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring."
[0036] As described herein, compounds of the present disclosure may contain "optionally substituted" moieties. In general, the term "substituted," whether preceded by the term "optionally" or not, means that one or more hydrogens of the specified moiety are replaced with a suitable substituent. In some embodiments, an "optionally substituted" group may have a suitable substituent at any substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from the specified groups, the substituents may be the same or different at each position. In some embodiments, an "optionally substituted" group refers to a group having 0-5 substituents independently selected from the specified groups. In some embodiments, an "optionally substituted" group refers to a group having 0-3 substituents independently selected from the specified groups. Combinations of substituents envisioned by the present disclosure are preferably those that result in the formation of stable or chemically feasible compounds. The term "stable," as used herein, refers to a compound that is substantially unchanged when subjected to conditions that enable its production, detection, and, in certain embodiments, its recovery, purification, and use for one or more of the purposes disclosed herein.
[0037] The monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen; -(CH 2 ) 0~4 R°;-(CH 2 ) 0~4 OR°;-O-(CH 2 ) 0~4 C(O)OR°;-(CH 2 ) 0~4 CH(OR°) 2 ;-(CH 2 ) 0~4 SR°;-(CH 2 ) 0~4 Ph, which may be substituted by R°; -(CH 2 ) 0~4 O(CH 2 ) 0~1Ph (which may be substituted by R°); -CH=CHPh (which may be substituted by R°); -NO 2 ;-CN;-N 3 ;-(CH 2 ) 0~4 N(R°) 2 ;-(CH 2 ) 0~4 N(R°)C(O)R°;-N(R°)C(S)R°;-(CH 2 ) 0~4 N(R°)C(O)NR° 2 ;-N(R°)C(S)NR° 2 ;-(CH 2 ) 0~4 N(R°)C(O)OR°;-N(R°)N(R°)C(O)R°;-N(R°)N(R°)C(O)NR° 2 ;-N(R°)N(R°)C(O)OR°;-(CH 2 ) 0~4 C(O)R°;-C(S)R°;-(CH 2 ) 0~4 C(O)OR°;-(CH 2 ) 0~4 C(O)SR°;-(CH 2 ) 0~4 C(O)OSiR° 3 ;-(CH 2 ) 0~4 OC(O)R°;-OC(O)(CH 2 ) 0~4 SR-, SC(S)SR°;-(CH 2 ) 0~4 SC(O)R°;-(CH 2 ) 0~4 C(O)NR° 2 ;-C(S)NR° 2 ;-C(S)SR°;-SC(S)SR°,-(CH 2 ) 0~4 OC(O)NR° 2 ;-C(O)N(OR°)R°;-C(O)C(O)R°;-C(O)CH 2 C(O)R°;-C(NOR°)R°;-(CH 2 ) 0~4 SSR°;-(CH 2 ) 0~4 S(O) 2 R°;-(CH2 ) 0~4 S(O) 2 OR°;-(CH 2 ) 0~4 OS(O) 2 R°;-S(O) 2 NR° 2 ;-(CH 2 ) 0~4 S(O)R°;-N(R°)S(O) 2 NR° 2 ;-N(R°)S(O) 2 R°;-N(OR°)R°;-C(NH)NR° 2 ;-P(O) 2 R°;-P(O)R° 2 ;-OP(O)R° 2 ;-OP(O)(OR°) 2 ;SiR° 3 ;-(C 1~4 Linear or branched alkylene)ON(R°) 2 ; or -(C 1~4 Linear or branched alkylene)C(O)ON(R°) 2 wherein each R° is optionally substituted as defined below and is independently hydrogen, C 1~6 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0~1 Ph, or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or, notwithstanding the above definitions, two independent occurrences of R° together with their intervening atoms form a 3-12 membered saturated monocyclic or bicyclic ring, partially unsaturated monocyclic or bicyclic ring, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which rings may be optionally substituted as defined below.
[0038] Monovalent substituents on R° (or the ring formed by two independent occurrences of R° taken together with their intervening atoms) are independently halogen, -(CH 2 ) 0~2 R ●, -(Halo R ● ), -(CH 2 ) 0~2 OH, -(CH 2 ) 0~2 OR ● , -(CH 2 ) 0~2 CH(OR ● ) 2 ;-O(HaloR ● ), -CN, -N 3 , -(CH 2 ) 0~2 C(O)R ● , -(CH 2 ) 0~2 C(O)OH, -(CH 2 ) 0~2 C(O)OR ● , -(CH 2 ) 0~2 S.R. ● , -(CH 2 ) 0~2 SH, -(CH 2 ) 0~2 NH 2 , -(CH 2 ) 0~2 NHR ● , -(CH 2 ) 0~2 NR ● 2 , -NO 2 , -SiR ● 3 , -OSiR ● 3 , -C(O)SR ● 、 -(C 1~4 Linear or branched alkylene)C(O)OR ● Or -SSR ● and R ● Each of is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens; 1~4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0~1or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such divalent substituents on a saturated carbon atom of R° include =O and =S.
[0039] Divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =O, =S, =NNR * 2 , =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O) 2 R * , =NR * , =NOR * , -O(C(R * 2 )) 2~3 O- or -S(C(R * 2 )) 2~3 R that contains S- and occurs independently * each represents hydrogen, C which may be substituted as defined below 1~6 A 5-6 membered unsubstituted saturated ring, partially unsaturated ring, or aryl ring having 0-4 heteroatoms independently selected from aliphatic, nitrogen, oxygen, or sulfur. Divalent substituents attached to adjacent substitutable carbons of an "optionally substituted" group include -O(CR * 2 ) 2~3 R containing O- and occurring independently * each represents hydrogen, C which may be substituted as defined below 1~6 A 5-6 membered unsubstituted saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from aliphatic, nitrogen, oxygen, or sulfur. A tetravalent substituent attached to adjacent substitutable methylene carbons of an "optionally substituted" group, when depicted with the methylene bearing it, is: [ka] A dicobalt hexacarbonyl cluster is represented by the formula:
[0040] R * Preferred substituents on the aliphatic groups are halogen, -R ● , -(Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH 2 , -NHR ● , -NR ● 2 OR -NO 2 and R ● each is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens, and independently represents C 1~4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0~1 Ph, or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0041] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R † , -NR † 2 , -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CH 2 C(O)R † , -S(O) 2 R † , -S(O) 2 NR † 2 , -C(S)NR † 2 , -C(NH)NR † 2 or -N(R † )S(O) 2 R † Contains R † each independently represents hydrogen, C which may be substituted as defined below1~6 aliphatic, unsubstituted -OPh, or a 5-6 membered unsubstituted saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or, regardless of the above definition, two independently occurring R † together with their intervening atoms form an unsubstituted 3-12 membered saturated monocyclic or bicyclic ring, partially unsaturated monocyclic or bicyclic ring, or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0042] R † Suitable substituents on the aliphatic group include, independently, halogen, -R ● , -(Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH 2 , -NHR ● , -NR ● 2 OR -NO 2 Contains R ● each is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens, and independently represents C 1~4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0~1 Ph, or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0043] In some embodiments, an "optionally substituted aliphatic" group refers to an aliphatic group, as defined above, that is substituted with 0-5 substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, phenyl, azide, or alkyne, wherein the phenyl is selected from the group consisting of halogen, -CH 3 , -CF 2 H, -CF 3 , -OCH 3or -OH. For example, an "optionally substituted aliphatic" group is a group selected from -C 6 H 5 A methyl group substituted with a group, i.e., a benzyl group (-CH 2 C 6 H 5 ) can be used to refer to
[0044] In some embodiments, an "optionally substituted aliphatic" group refers to an aliphatic group, as defined above, that is substituted with 0-3 substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, oxo, phenyl, azide, or alkyne, wherein the phenyl is selected from the group consisting of halogen, -CH 3 , -CF 2 H, -CF 3 , -OCH 3 or -OH. For example, an "optionally substituted aliphatic" group is a group selected from CH 2 C 6 H 5 It may refer to the group, i.e., a methyl group substituted by a benzyl group.
[0045] Protecting hydroxyl groups are well known in the art and are described in Wuts, PGM Protecting Groups in Organic Synthesis, 5, incorporated herein by reference in its entirety. thEd., New York, John Wiley & Sons, 2014. Examples of suitable protected hydroxyl groups further include, but are not limited to, esters, carbonates, sulfonates, allyl ethers, ethers, silyl ethers, alkyl ethers, aryl alkyl ethers, and alkoxy alkyl ethers. Examples of suitable esters include formates, acetates, propionates, pentanoates, crotonates, and benzoates. Examples of suitable esters include formates, benzoylformates, chloroacetates, trifluoroacetates, methoxyacetates, triphenylmethoxyacetates, p-chlorophenoxyacetates, 3-phenylpropionates, 4-oxopentanoates, 4,4-(ethylenedithio)pentanoates, pivaloates (trimethylacetates), crotonates, 4-methoxy-crotonates, benzoates, p-benzylbenzoates, and 2,4,6-trimethylbenzoates. Examples of carbonates include 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl carbonates. Examples of silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl ether and other trialkylsilyl ethers. Examples of alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl and allyl ethers or their derivatives. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl and tetrahydropyran-2-yl ether.Examples of arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl ethers.
[0046] Protected amines are well known in the art and include those described in detail in Wuts (2014). Mono-protected amines further include, but are not limited to, aralkyl amines, carbamates, allyl amines, amides, and the like. Examples of mono-protected amino moieties include t-butyloxycarbonylamino (-NHBOC), ethyloxycarbonylamino, methyloxycarbonylamino, trichloroethyloxycarbonylamino, allyloxycarbonylamino (-NHAlloc), benzyloxocarbonylamino (-NHCBZ), allylamino, benzylamino (-NHBn), fluorenylmethylcarbonyl (-NHFmoc), formamide, acetamide, chloroacetamide, dichloroacetamide, trichloroacetamide, phenylacetamide, trifluoroacetamide, benzamide, t-butyldiphenylsilyl, and the like. Di-protected amines include amines substituted with two substituents independently selected from those listed above as mono-protected amines, and further include cyclic imides such as phthalimide, maleimide, succinimide, and the like. Diprotected amines also include pyrroles, such as 2,2,5,5-tetramethyl-[1,2,5]azadisilolidine, and azides.
[0047] Protected aldehydes are well known in the art and include those described in detail in Wuts (2014). Protected aldehydes further include, but are not limited to, acyclic acetals, cyclic acetals, hydrazones, imines, and the like. Examples of such groups include dimethyl acetal, diethyl acetal, diisopropyl acetal, dibenzyl acetal, bis(2-nitrobenzyl) acetal, 1,3-dioxane, 1,3-dioxolane, semicarbazones, and derivatives thereof.
[0048] Protected carboxylic acids are well known in the art and include those described in detail in Wuts (2014). Protected carboxylic acids include, but are not limited to, optionally substituted C 1~6 Further included are aliphatic esters, optionally substituted aryl esters, silyl esters, activated esters, amides, hydrazides, etc. Examples of such ester groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl and phenyl esters, each group being optionally substituted. Further protected carboxylic acids include oxazolines and orthoesters.
[0049] Protected thiols are well known in the art and include those described in detail in Wuts (2014). Protected thiols further include, but are not limited to, disulfides, thioethers, silyl thioethers, thioesters, thiocarbonates, and thiocarbamates. Examples of such groups include, but are not limited to, alkyl thioethers, benzyl and substituted benzyl thioethers, triphenylmethyl thioethers, and trichloroethoxycarbonyl thioesters, to name a few.
[0050] Unless otherwise indicated, structures depicted herein are also intended to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure, such as the R and S configurations, Z and E double bond isomers, and Z and E conformational isomers for each asymmetric center. Thus, single stereochemical isomers of the compounds as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures are within the scope of the disclosure. Unless otherwise indicated, all tautomers of the compounds of the disclosure are within the scope of the disclosure. Additionally, unless otherwise indicated, structures depicted herein are also intended to include compounds that differ only by the presence of one or more isotopically enriched atoms. For example, the replacement of hydrogen by deuterium or tritium, or 13 C or 14Compounds having this structure, except for the replacement of a carbon with a C-rich carbon, are within the scope of this disclosure. Such compounds are useful, for example, in neutron scattering experiments, as analytical tools or as probes in biological assays.
[0051] As used herein, the term "detectable moiety" is used interchangeably with the term "label" and refers to any moiety that is detectable (e.g., primary labels and secondary labels). A "detectable moiety" or "label" is the radical of a compound that is detectable.
[0052] A "primary" label is a radioisotope-containing moiety (e.g., 32 P, 33 P, 35 S or 14 C-containing moiety), mass tags and fluorescent labels, which without further modification are reporter groups that produce a signal that can be detected.
[0053] "Secondary" labels include moieties such as biotin or protein antigens that require the presence of a second compound to generate a detectable signal. For example, in the case of a biotin label, the second compound can include a streptavidin-enzyme conjugate. In the case of an antigen label, the second compound can include an antibody-enzyme conjugate. Furthermore, certain fluorescent groups can act as secondary labels by transferring energy to another compound or group in the process of non-radioactive fluorescence resonance energy transfer (FRET), which then generates a signal that is detected.
[0054] The terms "fluorescent label", "fluorescent group", "fluorescent compound", "fluorescent dye" and "fluorophore" as used herein refer to a compound or moiety that absorbs light energy at a defined excitation wavelength and emits light energy at a different wavelength. Examples of fluorescent compounds include, but are not limited to: Alexa Fluor dyes (Alexa Fluor350, Alexa Fluor488, Alexa Fluor532, Alexa Fluor546, Alexa Fluor568, Alexa Fluor594, Alexa Fluor633, Alexa Fluor660 and Alexa Fluor680), AMCA, AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY530 / 550, BODIPY558 / 568, BODIPY564 / 570, BODIPY576 / 589, BODIPY581 / 591, BODIPY630 / 650, BODIPY650 / 665), carboxyrhodamine 6G, carboxy-X-rhodamine (ROX), cascade blue, cascade yellow, coumarin 343, cyanine dyes (Cy3, Cy5, Cy3.5, Cy5.5), dansyl, dapoxyl, dialkylaminocoumarin, 4',5'-dichloro-2',7'-dimethoxy-fluorescein, DM-NERF, eosin, erythrosine, fluorescein, FAM, hydrazine These include roxycoumarin, IRDyes (IRD40, IRD700, IRD800), JOE, Lissamine rhodamine B, Marina Blue, Methoxycoumarin, Naphthofluorescein, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, PyMPO, Pyrene, Rhodamine B, Rhodamine 6G, Rhodamine Green, Rhodamine Red, Rhodol Green, 2',4',5',7'-Tetra-bromosulfone-fluorescein, Tetramethyl-rhodamine (TMR), Carboxytetramethylrhodamine (TAMRA), Texas Red, and Texas Red-X.
[0055] The term "substrate" as used herein refers to any material or polymeric complex to which the multiblock copolymer can be attached. Examples of commonly used substrates include, but are not limited to, glass surfaces, silica surfaces, plastic surfaces, metal surfaces, surfaces containing metal or chemical coatings, membranes (e.g., nylon, polysulfone, silica), microbeads (e.g., latex, polystyrene or other polymers), porous polymer matrices (e.g., polyacrylamide gels, polysaccharides, polymethacrylates), polymeric complexes (e.g., proteins, polysaccharides).
[0056] Unless otherwise indicated, a radioisotope-containing moiety is an optionally substituted hydrocarbon group that contains at least one radioisotope. Unless otherwise indicated, a radioisotope-containing moiety contains 1-40 carbon atoms and one radioisotope. In certain embodiments, a radioisotope-containing moiety contains 1-20 carbon atoms and one radioisotope.
[0057] The terms "isotopically enriched" or "isotopically enriched" refer to altering the relative abundance of isotopes, thus producing forms of an element that are enriched in one particular isotope and depleted in others. For example, C 14 The compounds are said to be isotopically enriched.
[0058] The term "as received" when referring to the use of solvents, reagents, resins or other components used in a chemical reaction or isolation refers to using them as provided by the manufacturer without any additional isolation and / or purification.
[0059] As used herein, the term "hydrophobic molecule" refers to chemical compounds, drugs, therapeutic agents or active pharmaceutical ingredients, and pharma-ceutically acceptable salts thereof.
[0060] As used herein, the terms "drug," "therapeutic agent," "pharmaceutical product," "medicine" and their derivatives are used interchangeably and refer to substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease.
[0061] As used herein, the terms "drug-loaded" and "encapsulated," and their derivatives, are used interchangeably. According to the present disclosure, the term "drug-loaded" micelles refers to micelles that have a drug or therapeutic agent located within the core of the micelle. In certain instances, the drug or therapeutic agent is located at the interface between the core and the hydrophilic corona. This is also referred to as a drug or therapeutic agent that is "encapsulated" within the micelle.
[0062] As used herein, "weight loading" refers to the ratio of drug to the total drug product formulation, which may include, but is not limited to, drug, excipients, and copolymers. Weight loading is expressed as a weight percentage (% w / w), e.g., 20 mg of drug in a total formulation further containing 90 mg of cryoprotectant and 90 mg of copolymer is expressed as a 10% weight loading (20 / (20+90+90)=10%).
[0063] As used herein, "feed ratio" refers to the ratio of drug combined with the copolymer during the manufacture of the drug product. Feed ratio is expressed as a weight percentage (% w / w), for example, 100 mg of drug combined with 500 mg of copolymer (regardless of other components) is expressed as a feed ratio of 20% (100 / 500=20%).
[0064] As used herein, "high shear mix" or "high shear mixing" refers to dispersing a combination of components into a normally immiscible continuous phase by emulsification, sonication or microfluidization.
[0065] As used herein, "unit dosage form" or "unit dose form" refers to a physically separate unit of preparation suitable for the subject to be treated.However, it will be understood that the total amount of the composition of the present disclosure to be used per day will be determined by the attending physician within the scope of sound medical judgment.The specific effective dose level for any particular subject or organism will depend on various factors, including the disorder to be treated and the severity of the disorder, the activity of the specific active agent used, the specific composition used, the age, weight, general health, sex and diet of the subject, the time of administration and the excretion rate of the specific active agent used, the duration of treatment, the drugs and / or additional therapies used in combination with or simultaneously with the specific compound used, and similar factors well known in the medical arts.
[0066] As used herein, "drug product" refers to a therapeutic agent and one or more "excipients" selected from, but not limited to, tonicity agents, cryoprotectants, multiblock copolymers, stabilizers, anti-adherents, binders, coatings, colorants, disintegrants, flavorings, glidants, lubricants, preservatives, adsorbents, sweeteners, and vehicles. As will be appreciated by those skilled in the art, the amount of each excipient will depend on the therapeutic agent, the route of administration, the desired biological endpoint, and the target cells or tissues.
[0067] As used herein, "cryoprotectant" or "cryoprotectant" refers to a compound that prevents freezing or prevents freezing-related damage or degradation to other compounds, including, but not limited to, sugars, monosaccharides, disaccharides, polyalcohols, amino acids, glycine, polyvinylpyrrolidine, polyethylene glycol, mannitol, sorbitol, sucrose, glucose, raffinose, sucralose, lactose, trehalose, dextran, and dextrose.
[0068] As used herein, "therapeutically effective amount" refers to an amount of a substance (e.g., a therapeutic agent, composition and / or formulation) that induces a desired biological response. In some embodiments, a therapeutically effective amount of a substance is an amount that, when administered as part of a dosing regimen to a subject suffering from or susceptible to a disease, disorder and / or condition, is sufficient to treat, diagnose, slow the progression of, and / or delay the onset of the disease, disorder and / or condition. As will be understood by those skilled in the art, the effective amount of a substance can vary depending on factors such as the desired biological endpoint, the substance delivered, the target cell or tissue, etc. For example, an effective amount of a compound in a formulation for treating a disease, disorder and / or condition is an amount that relieves, improves, alleviates, inhibits, slows the progression of, delays the onset of, reduces the severity of, and / or reduces the incidence of one or more symptoms or characteristics of the disease, disorder and / or condition. In some embodiments, a "therapeutically effective amount" refers to at least the minimal amount of a compound or a composition containing a compound sufficient to treat one or more symptoms of a disease or disorder associated with a proliferative disease, such as cancer.
[0069] The term "subject," as used herein, means a mammal and includes humans and animal subjects such as domestic animals (eg, horses, dogs, cats, etc.).
[0070] The term "treat" or "treating" as used herein refers to partially or completely alleviating, inhibiting, delaying the onset of, slowing the progression of, improving, and / or relieving a disease or disorder, or one or more symptoms of a disease or disorder. As used herein, the terms "treatment", "treat" and "treating" refer to partially or completely alleviating, inhibiting, delaying the onset of, slowing the progression of, improving, and / or relieving a disease or disorder, or one or more symptoms of a disease or disorder described herein. In some embodiments, treatment may be performed after one or more symptoms have developed. In some embodiments, the term "treating" includes preventing, slowing, or stopping the progression of a disease or disorder. In other embodiments, treatment may be performed in the absence of symptoms. For example, treatment may be performed in a susceptible individual prior to the onset of symptoms (e.g., taking into account the history of symptoms and / or taking into account genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence. Thus, in some embodiments, the term "treating" includes preventing the recurrence or recurrence of a disease or disorder.
[0071] The term "parenteral" or "parenterally" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques for administration. Preferably, the composition is administered intraperitoneally or intravenously. The sterile injectable form of the composition of the present disclosure can be an aqueous or oily suspension. These suspensions can be formulated according to techniques known in the art using dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be used are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are commonly used as solvents or suspending media.
[0072] The term "TYN-21" is understood to refer to a formulation of paclitaxel, TFS-2 and trehalose, where the paclitaxel provides a weight loading of about 13% ± 2% by weight of the formulation.
[0073] The term "TYN-38" is understood to refer to a formulation of SN-38, TFS-3 and trehalose, where SN-38 provides a weight loading of about 10% ± 2% by weight of the formulation.
[0074] 3. Description of Exemplary Embodiments: 3.1 Multiblock copolymers In some aspects, the present disclosure relates to a multi-block copolymer comprising a poly(sarcosine) block and a D,L-mixed poly(amino acid) block. In certain embodiments, the present disclosure relates to a multi-block copolymer of formula I: [ka] (In the formula, R 1a is H or an optionally substituted aliphatic group, R 1b is H or an optionally substituted aliphatic group, R 2 is H, an optionally substituted aliphatic group, or CO-(C1-C6) aliphatic; R y are each independently a D-amino acid side chain; R z are each independently an L-amino acid side chain; x is 125 to 350; y is between 5 and 35; z is 5 to 35. to provide.
[0075] In some aspects, the present disclosure relates to multi-block copolymers in which the hydrophilic block comprises a polymer of N-methylglycine. Those skilled in the art will recognize that other N-alkylglycines can be used to generate water-soluble blocks (see Robinson, JW et al. Macromolecules 2013, 46(3), 580). In some embodiments, the present disclosure includes multi-block copolymers in which the hydrophilic block is poly(N-methylglycine), poly(N-ethylglycine), poly(N-{n-propyl})glycine, poly(N-isopropyl)glycine or poly(N-allyl)glycine. In some aspects, the present disclosure also includes mixtures of two or more N-alkylglycines used to construct the water-soluble block, such as a mixture of N-methylglycine and N-ethylglycine.
[0076] In some aspects, the present disclosure provides a method for the preparation of a 1a and R 1b In some embodiments, the multi-block copolymer of formula I includes a poly(sarcosine) block beginning with an amine-containing moiety having an optionally substituted aliphatic group represented by 1a is hydrogen, and R 1b is an optionally substituted aliphatic group. In some embodiments, R 1ais an optionally substituted aliphatic group or hydrogen, R 1b is an optionally substituted aliphatic group. In some embodiments, the present disclosure provides a multi-block copolymer of formula I that can be provided with an otherwise absent functional group, including, but not limited to, a detectable moiety, a fluorescent label, or a substrate, R 1a and R 1b Those skilled in the art envision substitutions in R 1a and R 1b It is recognized that numerous permutations of R are possible. 1a and R 1b Substitutions on include, but are not limited to, in some embodiments, optionally substituted benzyl groups, optionally substituted hydrocarbons, optionally substituted silyl groups, poly(amino acid) polymers, poly(ethylene glycol) polymers, poly(N-isopropylacrylamide) polymers, poly(acrylamide) polymers, poly(2-oxazoline) polymers, poly(ethyleneimine), poly(acrylic acid) polymers, poly(methacrylate) polymers, poly(vinyl alcohol) polymers, poly(vinylpyrrolidone) polymers, and their corresponding amine salts. 1a The aliphatic group is selected from (C1-C6) alkyl, (C1-C6) alkene, (C1-C6) alkyne, or (C3-C10) cycloalkyl, wherein the (C1-C6) alkyl, (C1-C6) alkene, (C1-C6) alkyne, or (C3-C10) cycloalkyl is substituted with 0-5 halogen, hydroxy, cyano, nitro, oxo, or phenyl, wherein the phenyl is substituted with halogen, -CH 3 , -CF 2 H, -CF 2 , -OCH 3 or -OH. In some embodiments, R 1bThe aliphatic group is selected from (C1-C6) alkyl, (C1-C6) alkene, (C1-C6) alkyne, or (C3-C10) cycloalkyl, wherein the (C1-C6) alkyl, (C1-C6) alkene, (C1-C6) alkyne, or (C3-C10) cycloalkyl is substituted with 0-5 halogen, hydroxy, cyano, nitro, oxo, or phenyl groups, wherein the phenyl is substituted with halogen, -CH 3 , -CF 2 H, -CF 2 , -OCH 3 or -OH. In some embodiments, R 1b benzyl, methoxybenzyl, neopentyl (i.e., CH 2 C(CH 3 ) 3 ) or a hexyl group. In a preferred embodiment, R 1a is H and R 1b is neopentyl. In another preferred embodiment, R 1a is H and R 1b is benzyl. In another preferred embodiment, R 1a is H and R 1b is p-methylbenzyl. In another preferred embodiment, R 1a is H and R 1b is p-methoxybenzyl. In another preferred embodiment, R 1a is H and R 1b is n-hexyl.
[0077] In certain embodiments, the present disclosure relates to multi-block copolymers comprising D,L-mixed poly(amino acid) blocks comprising amino acids such that the block as a whole is hydrophobic. R y and R zrepresent D- and L-amino acids, respectively. Although a D,L-mixed poly(amino acid) block may contain one or more natural or unnatural amino acid side groups that are not generally considered to be hydrophobic, it will be understood by those skilled in the art that the inclusion of an amino acid or unnatural amino acid side group that is hydrophobic may render the entire block hydrophobic. For example, in certain circumstances, tyrosine is considered a hydrophilic amino acid due to its phenolic functional group, but (tyrosine) 20 -co-(leucine) 30 The poly(amino acid) block is rendered hydrophobic overall, in part, by the inclusion of a significant amount of leucine (e.g., excess hydrophobic units), which is generally considered in the art to be a hydrophobic amino acid. It is also understood that amino acid side chain protecting groups can convert an amino acid generally considered to be hydrophilic into an amino acid generally considered to be hydrophobic. For example, glutamic acid is generally considered in the art to be a hydrophilic amino acid. However, protection of the carboxylic acid can render the amino acid side chain hydrophobic, as in the case of γ-benzyl-glutamic acid.
[0078] In certain embodiments, for compositions represented by formula I, R y are derived from hydrophilic D-amino acids, and R z are each derived from a hydrophobic L-amino acid.
[0079] In certain embodiments, for compositions represented by formula I, R y are derived from hydrophobic D-amino acids, and R z are each derived from a hydrophilic L-amino acid.
[0080] In certain embodiments, for compositions represented by formula I, R y are derived from hydrophobic D-amino acids, and R z are each derived from a hydrophobic L-amino acid.
[0081] In some embodiments, R yare each independently the side chain of γ-benzyl-D-glutamic acid, D-leucine, D-tyrosine, D-phenylalanine, D-alanine, D-valine, D-isoleucine, D-norleucine, O-acetyl-D-tyrosine, O-benzyl-D-tyrosine, or ε-benzyl-D-lysine. z are each independently the side chain of γ-benzyl-L-glutamic acid, L-leucine, L-tyrosine, L-phenylalanine, L-alanine, L-valine, L-isoleucine, L-norleucine, O-acetyl-L-tyrosine, O-benzyl-L-tyrosine, or ε-benzyl-L-lysine. y are each independently the side chain of D-leucine, D-phenylalanine, or D-tyrosine. z are each independently the side chains of L-leucine, L-phenylalanine, or L-tyrosine.
[0082] As described above, for compositions represented by Formula I, x and y represent the number of residues for natural or unnatural D-amino acids and L-amino acids, respectively, in the poly(amino acid) block. y and R z It is recognized that the selection of x, as well as the values of y and z, will vary depending on the final role that the final multiblock copolymer is to play. It is also understood that for some desired roles, the length of the sarcosine block represented by x is not independent of y and z.
[0083] In some aspects, the present disclosure relates to multi-block copolymers in which one of the core amino acids, whether D- or L-amino acid, is replaced by another amino acid that disrupts the helical structure normally adopted by isotactic poly(amino acid) polymers. Such amino acids contemplated by the present disclosure include, but are not limited to, N-substituted glycines (e.g., sarcosine), proline and / or glycine.
[0084] In some embodiments, the present disclosure provides a multi-block copolymer of formula I, 2 is H, an optionally substituted aliphatic group, CO-(C1-C6) aliphatic or -COCH 3 The present disclosure relates to multi-block copolymers of formula I, which are selected from the group consisting of R 2 In some embodiments, substitutions in R 2 is selected such that an amide bond is formed. In a preferred embodiment, R 2 is an acetyl group. In another preferred embodiment, R 2 Those skilled in the art will recognize that isotopically enriched materials can be useful probes in biological assays, such as quantitative whole body autoradiography (QWBA) assays, which are useful for determining the distribution of compositions in animals.
[0085] In certain embodiments, the present disclosure provides a multi-block copolymer of formula I (In the formula, R 1a is an optionally substituted aliphatic group; R 1b is H, R 2 is H or COCH 3 and R y are each independently a D-amino acid side chain; R z are each independently an L-amino acid side chain; x is 125 to 350; y is between 5 and 35; z is 5 to 35. to provide.
[0086] In certain embodiments, the present disclosure provides a multi-block copolymer of formula I (In the formula, R 1ais an optionally substituted aliphatic group; R 1b is H, R 2 is H or COCH 3 and R y are the amino acid side chains corresponding to the side chain of D-leucine, R z are amino acid side chains corresponding to the side chain of L-tyrosine, x is 125 to 350; y is between 5 and 35; z is 5 to 35. to provide.
[0087] One embodiment of the present disclosure is a compound having the following structure: [ka] The present invention provides a multi-block copolymer represented by:
[0088] Another embodiment of the present disclosure is a compound having the following structure: [ka] The present invention provides a multi-block copolymer represented by:
[0089] One embodiment of the present disclosure is a compound having the following structure: [ka] The present invention provides a multi-block copolymer represented by:
[0090] One embodiment of the present disclosure is a compound having the following structure: [ka] The present invention provides a multi-block copolymer represented by:
[0091] One embodiment of the present disclosure is a compound having the following structure: [ka] The present invention provides a multi-block copolymer represented by:
[0092] One embodiment of the present disclosure is a compound having the following structure: [ka] The present invention provides a multi-block copolymer represented by:
[0093] 3.2 Synthesis of multiblock copolymers In certain embodiments, the present disclosure provides a method for preparing a multi-block copolymer comprising a poly(sarcosine) block and a D,L-mixed poly(amino acid) block. One embodiment of a general method for preparing said multi-block copolymer is illustrated in Scheme 1 and includes the steps of: 1) initiating the polymerization of a sarcosine NCA (Formula III) with a suitable amine-containing initiator (Formula II); 2) adding a mixture comprising one or more D-amino acid NCAs (Formula IVy) and one or more L-amino acid NCAs (Formula IVz) to the living polymerization. Scheme [ka]
[0094] In some cases, it may be advantageous to add the NCA to the reaction as a solution rather than a solid. For example, during large-scale production, a solution is easier to handle than a solid. In some embodiments of the present disclosure, the NCA is added to the reaction as a solid, regardless of whether it is Formula III, Formula IVy, or Formula IVz. In other embodiments of the present disclosure, the NCA is added to the reaction as a solution, regardless of whether it is Formula III, Formula IVy, or Formula IVz. In certain embodiments, the solvent is the same solvent used to solubilize the initiator II. In a preferred embodiment, the solvent is N,N,-dimethylformamide. In a preferred embodiment, the solvent is N,N-dimethylacetamide.
[0095] As described herein, in certain embodiments, the D,L-mixed poly(amino acid) blocks of formula I are prepared by polymerization of NCAs derived from natural and non-natural amino acids. In some embodiments, the NCAs of formula IVy and formula IVz are selected such that the resulting poly(amino acid) block is overall hydrophobic. As previously discussed, the inclusion of amino acids that are generally considered hydrophilic does not necessarily prevent the block from being overall hydrophobic. Thus, in certain embodiments, the NCAs of formula IVy are derived from hydrophilic D-amino acids and the NCAs of formula IVz are derived from hydrophobic L-amino acids. In other embodiments, the NCAs of formula IVy are derived from hydrophobic D-amino acids and the NCAs of formula IVz are derived from hydrophilic L-amino acids. In other embodiments, the NCAs of formula IVy are derived from hydrophobic D-amino acids and the NCAs of formula IVz are derived from hydrophobic L-amino acids.
[0096] In certain embodiments, the process illustrated in Scheme 1 is carried out in a single solvent. The solvent is capable of solubilizing the starting materials, the living polymer chains, and the final copolymer so that all materials remain in solution during the entire process. Solvents that contain amides are suitable for this process. In a preferred embodiment, the solvent is N,N-dimethylformamide (DMF). In another preferred embodiment, the solvent is N,N-dimethylacetamide (DMAc).
[0097] In certain embodiments, the initiator of formula II is a primary amine, R 1a is hydrogen and R 1b is an optionally substituted aliphatic group. In certain embodiments, the initiator of formula II is a secondary amine, and R 1a is an optionally substituted aliphatic group, R 1b is an optionally substituted aliphatic group. Those skilled in the art will recognize that many primary amines and many secondary amines are suitable for initiating polymerization reactions with NCAs. Initiators contemplated by the present disclosure include, but are not limited to, optionally substituted benzylamines, optionally substituted hydrocarbylamines, optionally substituted silylamines, poly(amino acid) polymers, poly(ethylene glycol) polymers, poly(N-isopropylacrylamide) polymers, poly(acrylamide) polymers, poly(2-oxazoline) polymers, poly(ethyleneimine), poly(acrylic acid) polymers, poly(methacrylate) polymers, poly(vinyl alcohol) polymers, poly(vinylpyrrolidone) polymers, and their corresponding amine salts. In a preferred embodiment, the initiator of formula II is selected from benzylamine, p-methylbenzylamine, p-methoxybenzylamine, or n-hexylamine. In a preferred embodiment, the initiator of formula II has the following structure: [ka] and neopentylamine represented by the formula:
[0098] In some embodiments, the present disclosure relates to methods of preparing compounds of formula I using reagents, solvents, resins and other components used in chemical reactions or isolation as received. In some embodiments, compounds of formula I are prepared without measures taken to exclude air and / or moisture (e.g., Schlenk technique). Those skilled in the art understand the advantages of NCA polymerization reactions under these conditions, as they reduce costs and increase the robustness of such processes.
[0099] The present disclosure also relates to the isolation of the multi-block copolymer of formula I from the reaction mixture using a single anti-solvent. In some embodiments, the ratio of the reaction mixture to the anti-solvent is such that the total amount used is minimized. Those skilled in the art recognize the advantage of using a minimum amount of anti-solvent, as it reduces the cost and complexity and allows the scale of preparation to be increased. Such ratios of the reaction mixture to the anti-solvent contemplated by the present disclosure include, but are not limited to, 1:0.25, 1:0.5, 1:1, 1:1.5, 1:2, 1:3, 1:4, 1:5, 1:10.
[0100] The present disclosure relates to the use of a single reaction solvent and a single anti-solvent.Those skilled in the art recognize that the use of only two solvents in total for the preparation of the compound of formula I is advantageous, because it minimizes the cost on a commercial scale under Good Manufacturing Practice (GMP) guidance, and requires only the procurement and quantification of the minimum number of solvents during release testing.In certain embodiments, the anti-solvent is selected from the list including, but not limited to, ketone-containing solvent, hydroxyl-containing solvent, ester-containing solvent, ether-containing solvent, hydrocarbon solvent, aromatic solvent, and aqueous solvent.
[0101] Anti-solvents contemplated in this disclosure include, but are not limited to, methyl ethyl ketone, acetone, butanone, ethanol, methanol, isopropanol, butanol, tert-butanol, methyl acetate, butyl acetate, diethyl ether, dioxane, tetrahydrofuran, hexane, heptane, toluene, benzene, water, and aqueous buffer solutions.
[0102] In a preferred embodiment, the anti-solvent is ethyl acetate. In another preferred embodiment, the anti-solvent is methyl tert-butyl ether.
[0103] As noted above, for compounds of formula I, R 2 is an optionally substituted aliphatic group. Those skilled in the art will recognize that R 2 When is H (Formula IV), treatment with a terminating agent results in R 2 It is recognized that the method of changing the substitution in R in Scheme 2 is 2 Such terminating agents, represented by -LG, are any R capable of reacting with the terminal amine of the compound of formula IV. 2 Contains a containing group. Scheme 2 [ka]
[0104] Those skilled in the art will recognize the structure R 2 It is recognized that a number of terminating agents of -LG can react with the terminal amine of the compound represented by formula V and its corresponding anion. 2 -LG terminating agents include anhydrides, sulfonyl halides and other acylating agents, as well as groups containing a leaving group (LG) susceptible to nucleophilic displacement. In a preferred embodiment, the terminating agent is acetic anhydride, represented by the following structure: [ka] It is.
[0105] One skilled in the art can easily determine the R2 It is recognized that treatment with a terminating agent represented by -LG may be performed at the end of the NCA polymerization to give a compound of formula V, thus making the method of preparing a compound of formula I a "one-pot" synthesis. 2 The treatment with -LG can be carried out after isolation of the compound of formula V from the reaction mixture in a "multi-step" process. In certain embodiments, the compound of formula I is prepared in a one-pot process. In other embodiments, the compound of formula I is prepared in a multi-step process.
[0106] 3.3 Micelles In certain embodiments, the present disclosure relates to polymeric micelles. It is understood that multi-block poly(amino acid) copolymers containing hydrophilic blocks and hydrophilic blocks spontaneously self-assemble into micelles in aqueous solution. Those skilled in the art recognize that poly(sarcosine) blocks are hydrophilic. Without wishing to be bound by any particular theory, it is believed that multi-block copolymers containing poly(sarcosine) and poly(amino acid) blocks that are hydrophobic as a whole form micelles, with the poly(sarcosine) blocks forming the hydrophilic corona and the hydrophobic poly(amino acid) blocks forming the core of the micelles.
[0107] The poly(amino acid) blocks of the present disclosure are composed of a mixture of D- and L-amino acids. Without wishing to be bound by any particular theory, it is believed that the incorporation of atactic poly(amino acid) blocks disrupts the formation of secondary and tertiary structures normally adopted by isotactic poly(amino acids) such as proteins. This results in the formation of micelles constructed from atactic poly(amino acid)-containing copolymers that have different physical properties than those of micelles constructed from equivalent isotactic poly(amino acid)-containing copolymers. The physical properties include, but are not limited to, critical micelle concentration, solubility, and drug loading efficiency.
[0108] In certain embodiments, the present disclosure relates to multiblock poly(amino acid) copolymers of formula I that can self-assemble into multimolecular micelles in aqueous solution when their concentration exceeds the critical micelle concentration. Such micelles are useful for encapsulating hydrophobic molecules, including, but not limited to, drugs, therapeutic agents, diagnostic agents, and probes.
[0109] 3.4 Drug burden In certain embodiments, the present disclosure relates to polymeric micelles that encapsulate hydrophobic molecules, thereby increasing the solubility of the molecules in aqueous solutions. Without wishing to be bound by any particular theory, it is believed that when a hydrophobic molecule is present in aqueous solution with the multiblock copolymer of formula I, the molecule is sequestered in the hydrophobic portion of the multiblock copolymer, which has the effect of increasing the solubility of the hydrophobic molecule. When the multiblock copolymer forms micelles, the hydrophobic molecule is sequestered in the hydrophobic core of the micelle and is therefore made water-soluble by the hydrophilic corona of the micelle. In certain embodiments, the hydrophobic molecule is a drug.
[0110] In some embodiments, the present disclosure provides a composition comprising a hydrophobic molecule and a multi-block copolymer of formula I. In some embodiments, the hydrophobic molecule is a drug. In certain embodiments, the present disclosure provides a drug-loaded micelle, where the drug is selected from the list including, but not limited to, paclitaxel, docetaxel, cabazitaxel, and SN-38, and pharma-ceutically acceptable salts thereof.
[0111] In some embodiments, the present disclosure provides a composition comprising multiblock copolymer TFS-1 and a hydrophobic molecule.In a preferred embodiment, the hydrophobic molecule is a drug selected from the list consisting of paclitaxel, docetaxel, cabazitaxel and SN-38, and pharma-ceutically acceptable salts thereof.
[0112] In some embodiments, the present disclosure provides a composition comprising multiblock copolymer TFS-2 and a hydrophobic molecule.In a preferred embodiment, the hydrophobic molecule is a drug selected from the list consisting of paclitaxel, docetaxel, cabazitaxel and SN-38, and pharma-ceutically acceptable salts thereof.
[0113] In some embodiments, the present disclosure provides a composition comprising the multiblock copolymer TFS-3 and a hydrophobic molecule. In a preferred embodiment, the hydrophobic molecule is a drug selected from the list consisting of paclitaxel, docetaxel, cabazitaxel and SN-38, and pharma-ceutically acceptable salts thereof.
[0114] The weight loading of a particular hydrophobic molecule depends on the particular composition of the multiblock copolymer of formula I. Those skilled in the art will recognize that various weight loadings of hydrophobic molecules are possible with the present disclosure. It will also be recognized that the weight loading can be adjusted to meet the needs of a particular formulation, such as solubility, stability, and reduced cost of manufacture of the resulting formulation. In some embodiments, the hydrophobic molecule is a drug, and the weight loading of the drug is between about 1% and about 25% of the composition.
[0115] In some embodiments, the disclosure provides a composition comprising a multi-block copolymer of formula I and a drug, wherein the drug is about 1% to about 5% of the composition.
[0116] In some embodiments, the disclosure provides a composition comprising a multi-block copolymer of formula I and a drug, wherein the drug is about 5% to about 10% of the composition.
[0117] In some embodiments, the disclosure provides a composition comprising a multi-block copolymer of formula I and a drug, wherein the drug is about 10% to about 15% of the composition.
[0118] In some embodiments, the disclosure provides a composition comprising a multi-block copolymer of formula I and a drug, wherein the drug is about 15% to about 20% of the composition.
[0119] In some embodiments, the disclosure provides a composition comprising a multi-block copolymer of formula I and a drug, wherein the drug is about 20% to about 25% of the composition.
[0120] 3.5 Drug Products The present disclosure provides a composition useful for encapsulating hydrophobic drugs, and such compositions can be provided as a drug product useful for treating patients in need thereof.In some embodiments, the present disclosure provides a drug product comprising a multiblock copolymer of formula I and a drug.Such compositions can further comprise an excipient as defined herein.
[0121] Certain embodiments of the present disclosure may be provided as a pharmaceutically acceptable composition. Such compositions include, but are not limited to, pills, tablets, capsules, aqueous suspensions or solutions, suppositories, creams, aerosols, syrups, films, skin patches, transdermal patches, vaginal rings, and eye drops. In a preferred embodiment, the pharmaceutically acceptable composition is a lyophilized powder.
[0122] The compositions of the present disclosure are capable of providing a therapeutically effective amount of a drug suitable for treating a subject in need thereof, hi a preferred embodiment, the subject is a human.
[0123] The present disclosure also provides compositions that can be administered to patients in need thereof. Routes of administration include, but are not limited to, parenteral, oral, sublingual, buccal, rectal, vaginal, ocular, aural, nasal, inhalation, spray, skin, subcutaneous, topical, systemic or transdermal. In some embodiments, the compositions of the present disclosure may be formulated as part of an implant or device, or may be formulated for slow or extended release. In a preferred embodiment, the route of administration is intravenous. In another preferred embodiment, the route of administration is via a central venous catheter. In another preferred embodiment, the route of administration is via a peripheral venous catheter.
[0124] In certain embodiments of the present disclosure, the compositions are formulated for oral administration in the form of, for example, capsules, cachets, pills, tablets, lozenges (using flavored bases, usually sucrose, and acacia or tragacanth), powders, granules, or as a solution or suspension in an aqueous liquid or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as a troche (using an inert base such as gelatin and glycerin or sucrose and acacia), etc.
[0125] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, etc.), the compositions of the present disclosure may be administered in the form of one or more pharma- ceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or one or more of the following: (1) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia; (3) humectants, such as glycerol; (4) agar, calcium carbonate, valerate, or other suitable soluble ... The pharmaceutical composition may be mixed with any of the following: disintegrating agents such as starch or tapioca, alginic acid, certain silicates and sodium carbonate; (5) dissolution retarders such as paraffin; (6) absorption promoters such as quaternary ammonium compounds; (7) wetting agents such as cetyl alcohol and glycerol monostearate; (8) absorbents such as kaolin and bentonite clay; (9) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical composition may also contain buffering agents. Solid compositions of a similar type may also be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols.
[0126] In some embodiments, the drug product of the present disclosure is formulated as a liquid dosage form for oral administration. Liquid dosage forms for oral administration include pharma- ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. Liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyline glycol, oils (e.g., cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol and fatty acid esters or sorbitan, and mixtures thereof. Oral compositions may also contain adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, coloring agents, fragrances and preservatives.
[0127] In certain embodiments, the compositions of the present disclosure are formulated for parenteral administration.As an example, the compositions of the present disclosure can be formulated for parenteral administration by further comprising one or more pharma- ceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders that can be reconstituted into sterile injectable solutions or dispersions immediately before use.Compositions for parenteral administration may contain antioxidants, buffers, bacteriostatic agents, and / or solutes that make the formulation isotonic with the blood of the intended recipient, or suspending agents, or thickening agents.Examples of suitable aqueous and non-aqueous vehicles that can be used in the pharmaceutical compositions of the present disclosure include water, Ringer's solution, isotonic salt solution, ethanol, polyols (e.g., 1,3-butanediol, glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. In a preferred embodiment, the compositions of the present disclosure are intended for parenteral administration and further comprise a vehicle selected from water, 1,3-butanediol, Ringer's solution, or isotonic sodium chloride solution.
[0128] The composition of the present disclosure can be administered for slow release, controlled release or extended release. The term "extended release" is widely recognized in the field of pharmaceutical science and is used herein to refer to the controlled release of an active compound or drug from a dosage form into an environment for an extended period of time, for example, more than or over an hour (throughout or during). An extended release dosage form releases drug at a substantially constant rate over an extended period of time, or a substantially constant amount of drug is released in an increasing manner over an extended period of time. The term "extended release" as used herein includes the terms "controlled release", "extended release", "sustained release", "delayed release" or "slow release" as these terms are used in pharmaceutical science. In some embodiments, the extended release dosage is administered in the form of a patch or pump.
[0129] 3.6 Methods for enhancing the solubility of hydrophobic molecules In certain embodiments, the present disclosure provides a method for increasing the solubility of hydrophobic molecules in aqueous solutions. As described above, the multiblock copolymers of the present disclosure can spontaneously self-assemble into micellar structures in aqueous solutions, with the hydrophilic poly(sarcosine) blocks forming the corona and the hydrophobic poly(amino acid) blocks forming the core of the micelles. If a hydrophobic molecule is present during this assembly, the molecule can be sequestered (i.e., encapsulated) in the hydrophobic portion of the micelle. This has the effect of increasing the solubility of the hydrophobic molecule in aqueous solutions.
[0130] In one aspect, the present disclosure is directed to a method for increasing the solubility of a hydrophobic molecule in an aqueous solution, comprising encapsulating the hydrophobic molecule in a multi-block copolymer according to the present disclosure. One embodiment of the present disclosure provides a method for preparing a composition comprising a hydrophobic molecule and a cryoprotectant with enhanced solubility properties in an aqueous solution. A general method for providing the composition includes preparing an aqueous solution of a cryoprotectant and a multi-block copolymer according to the present disclosure. A solution of the hydrophobic molecule is prepared in an organic solvent, thereby resulting in an organic solution. The organic solution is added to the solution of the cryoprotectant and the multi-block copolymer while generating a uniform emulsion by shear mixing using a homogenizer. The uniform emulsion is processed through a microfluidizer. The aqueous solution of the cryoprotectant is processed through a microfluidizer extrusion solution by tangential flow filtration. The resulting solution is sterile filtered (e.g., aseptically filtered), filled into vials under sterile conditions, and lyophilized under sterile conditions. Suitable cryoprotectants include, but are not limited to, sugars, monosaccharides, disaccharides, polyhydric alcohols, amino acids, glycine, polyvinylpyrrolidine, polyethylene glycol, mannitol, sorbitol, sucrose, glucose, raffinose, sucralose, lactose, trehalose, dextran and dextrose. In a preferred embodiment, the cryoprotectant is trehalose.
[0131] 3.8. Manufacturing method In certain aspects, the present disclosure is directed to a method of preparing a drug product comprising a hydrophobic molecule and a copolymer of formula I.
[0132] In some embodiments, the present disclosure is directed to a method of preparing a sterile, lyophilized drug product comprising a hydrophobic molecule and a copolymer of Formula I. The drug product may be suitable for administration to a patient.
[0133] In some embodiments, the present disclosure is directed to a method for preparing a sterile, lyophilized drug product comprising a hydrophobic molecule, a copolymer of formula I, and a cryoprotectant. A general method for providing the drug product includes preparing a solution of a cryoprotectant and a copolymer of formula I in a mixture of aqueous tert-butanol. A hydrophobic molecule solution is prepared in tert-butanol. The hydrophobic molecule solution is added to the solution of a cryoprotectant and a copolymer of formula I, and the resulting solution is sterile filtered (e.g., aseptically filtered), filled into vials under sterile conditions, and lyophilized under sterile conditions. Suitable cryoprotectants include, but are not limited to, sugars, monosaccharides, disaccharides, polyhydric alcohols, amino acids, mannitol, glycine, polyvinylpyrrolidine, polyethylene glycol, sorbitol, sucrose, glucose, raffinose, sucralose, lactose, trehalose, dextran, and dextrose. In a preferred embodiment, the cryoprotectant is trehalose or glycine.
[0134] In some embodiments, the present disclosure provides: a) dissolving a hydrophobic molecule or a pharma- ceutically acceptable salt thereof, a copolymer of formula I, and optionally a cryoprotectant in aqueous tert-butanol, thereby forming a mixed solution; and b) freeze-drying the mixture, if necessary. The present invention is directed to a method of preparing a unit dosage form, comprising:
[0135] In some embodiments, the present disclosure provides: a) dissolving a hydrophobic molecule, or a pharma- ceutically acceptable salt thereof, in tert-butanol, thereby forming a hydrophobic molecule solution; b) dissolving the copolymer of formula I, and optionally a cryoprotectant, in aqueous tert-butanol, thereby forming a copolymer solution; c) mixing the hydrophobic molecule solution with the copolymer solution, thereby forming a mixed solution; and d) freeze-drying the mixture, if necessary. The present invention is directed to a method of preparing a unit dosage form, comprising:
[0136] In some embodiments, the present disclosure provides: a) dissolving a hydrophobic molecule, or a pharma- ceutically acceptable salt thereof, in tert-butanol, thereby forming a hydrophobic molecule solution; b) dissolving the copolymer of formula I, and optionally a cryoprotectant, in aqueous tert-butanol, thereby forming a copolymer solution; c) mixing the hydrophobic molecule solution with the copolymer solution, thereby forming a mixed solution; d) filtering the mixed solution, thereby forming a filtered solution; e) optionally lyophilizing the filtered solution. The present invention is directed to a method of preparing a unit dosage form, comprising:
[0137] In one aspect, the disclosure is directed to a method for preparing a sterile, freeze-dried drug product comprising a hydrophobic molecule and a copolymer of formula I. The drug product may be suitable for administration to a patient. One embodiment of the disclosure provides a method for preparing a sterile, freeze-dried drug product comprising a hydrophobic molecule, a copolymer of formula I, and a cryoprotectant. A general method for providing the drug product includes preparing an aqueous solution of a cryoprotectant and a copolymer of formula I. A hydrophobic molecule solution is prepared in an organic solvent. The hydrophobic molecule solution is added to the solution of a cryoprotectant and a copolymer of formula I while using a homogenizer to generate a uniform emulsion by shear mixing. The uniform emulsion is processed by a high shear mixer (e.g., a microfluidizer). The aqueous solution of a cryoprotectant is processed by extrusion solution by a high shear mixer by tangential flow filtration. The resulting solution is sterile filtered (e.g., aseptically filtered), filled into vials under sterile conditions, and freeze-dried under sterile conditions. Suitable cryoprotectants include, but are not limited to, sugars, monosaccharides, disaccharides, polyhydric alcohols, amino acids, glycine, polyvinylpyrrolidine, polyethylene glycol, mannitol, sorbitol, sucrose, glucose, raffinose, sucralose, lactose, trehalose, dextran and dextrose. In a preferred embodiment, the cryoprotectant is trehalose.
[0138] In some embodiments, the present disclosure provides: a) dissolving a hydrophobic molecule or a pharma- ceutically acceptable salt thereof, a copolymer of formula I, and optionally a cryoprotectant in an aqueous solution, thereby forming a mixed solution; b) treating the mixed solution with a high shear mixer, thereby forming a high shear mixed solution; and c) optionally lyophilizing the high shear mixed solution; The present invention is directed to a method of preparing a unit dosage form, comprising:
[0139] In some embodiments, the present disclosure provides: a) dissolving a hydrophobic molecule or a pharma- ceutically acceptable salt thereof in an organic solvent, thereby forming a hydrophobic molecule solution; b) dissolving the copolymer of formula I, and optionally a cryoprotectant, in an aqueous solution, thereby forming a copolymer solution; c) mixing the hydrophobic molecule solution with the copolymer solution, thereby forming a mixed solution; d) treating the mixed solution with a high shear mixer, thereby forming a high shear mixer solution; e) filtering the high shear mixer solution, thereby forming a filtered solution; and f) optionally lyophilizing the filtered solution. The present invention is directed to a method of preparing a unit dosage form, comprising:
[0140] In some embodiments, the present disclosure provides: a) dissolving a hydrophobic molecule or a pharma- ceutically acceptable salt thereof in an organic solvent, thereby forming a hydrophobic molecule solution; b) dissolving the copolymer of formula I, and optionally a cryoprotectant, in an aqueous solution, thereby forming a copolymer solution; c) mixing the hydrophobic molecule solution with the copolymer solution, thereby forming a mixed solution; d) treating the mixed solution with a high shear mixer, thereby forming a high shear mixer solution; e) treating the high shear mixer solution with a diafiltration system, thereby forming a diafiltered solution; f) filtering the diafiltered solution, thereby forming a filtered solution; and g) optionally lyophilizing the filtered solution. The present invention is directed to a method of preparing a unit dosage form, comprising:
[0141] 3.7 Examples The present disclosure provides a compound having the following structure: [ka] [ka] [ka] [ka] [ka] [ka] [ka] We envision a multiblock copolymer of the above. EXAMPLES
[0142] In order that this disclosure may be more fully understood, the following examples are set forth, it being understood that these examples are for illustrative purposes only and are not to be construed as limiting this disclosure in any way.
[0143] In examples where an amino acid or NCA includes the prefix "D," the corresponding amino acid or NCA is of the D-configuration. When such a prefix is absent, the corresponding amino acid or NCA is of the L-configuration.
[0144] In the examples, unless otherwise noted, all multi-block copolymers, even if not explicitly stated, including in the brief description, contain neopentylamino groups (CH 3 ) 3 CH 2 It is understood that the starting group is -NH-. For example, Sar x -bp-[D-Leu y -co-L-Tyr z ] means the following compound: [ka] This is a brief explanation of
[0145] Analysis method: The following analytical methods are utilized to characterize the compounds of the present disclosure.
[0146] Infrared (IR) Spectroscopy - All samples were analyzed using a PerkinElmer Spectrum100 FT-IR spectrometer equipped with a Universal ATR Sampling Accessory (Diamond / ZnSe). When using IR to monitor reactions, aliquots of approximately 100 μL were taken and measured directly. Solid samples were measured without further manipulation.
[0147] Nuclear Magnetic Resonance (NMR) Spectroscopy - All samples were analyzed on a 400 MHz spectrometer using the following parameters: 45° pulse, 2 s acquisition time, 5 s recycle delay, 16-32 transients.
[0148] Gel Permeation Chromatography (GPC) Analysis - Samples were analyzed using a Shimadzu LC-20AD pump with a 100 Å, 8×300 mm, 10 μm column for 2×PSS GRAM analysis; a 1000 Å, 8×300 mm, 10 μm column for 1×PSS GRAM analysis; a Wyatt TREOS II light scattering detector and a Wyatt Optilab T-rEX refractive index detector in series. Analytes were eluted using a mobile phase of DMF (50 mM) supplemented with LiBr at a flow rate of 1.0 mL. The column temperature was maintained at 45° C. A run time of 45 min was typically used. GPC number average molecular weight (Mn) and peak molecular weight (Mp) were calibrated using polystyrene molecular weight standards.
[0149] Paclitaxel HPLC Method - The assay and identity of paclitaxel was determined by high performance liquid chromatography with UV detection at 227 nm. The column utilized was a Phenomenex Gemini® 5 μm C18 (110 Å, 250×4.6 mm) at ambient temperature. The mobile phase consisted of a 60:40 (v / v) mixture of 10 mM sodium phosphate and acetonitrile. Paclitaxel drug product samples were prepared by dissolving the material in the mobile phase. Paclitaxel standards were prepared by dissolving the material in acetonitrile. Separation was achieved at a flow rate of 1.0 mL / min for a total run time of 12 minutes.
[0150] Cabazitaxel HPLC Method - The assay and identity of cabazitaxel was determined by high performance liquid chromatography with UV detection at 227 nm. The column utilized was a Phenomenex Gemini® 5 μm C18 (110 Å, 250×4.6 mm) at ambient temperature. The mobile phase consisted of a 60:40 (v / v) mixture of 10 mM sodium phosphate and acetonitrile. Cabazitaxel drug product samples were prepared by dissolving the material in the mobile phase. Cabazitaxel standards were prepared by dissolving the material in acetonitrile. Separation was achieved at a flow rate of 1.0 mL / min for a total run time of 8 minutes.
[0151] Docetaxel HPLC Method - Assay and identity of docetaxel was determined by high performance liquid chromatography with UV detection at 227 nm. The column utilized was a Phenomenex Gemini® 5 μm C18 (110 Å, 250×4.6 mm) at ambient temperature. The mobile phase consisted of a 60:40 (v / v) mixture of 10 mM sodium phosphate and acetonitrile. Docetaxel drug product samples were prepared by dissolving the material in the mobile phase. Docetaxel standards were prepared by dissolving the material in acetonitrile. Separation was achieved at a flow rate of 1.0 mL / min for a total run time of 8 minutes.
[0152] SN-38 HPLC Method - The assay and identity of SN-38 was determined by high performance liquid chromatography with UV detection at 265 nm. The column utilized was a Phenomenex Gemini® 5 μm C18 (110 Å, 250×4.6 mm) at ambient temperature. The mobile phase consisted of a 70:30 (v / v) mixture of 10 mM sodium phosphate (pH 3.5) and acetonitrile containing 0.1% (v / v) triethylamine. SN-38 drug product samples and standards were prepared by dissolving the material in a 7:3 (v / v) mixture of acetonitrile and DMSO. Separation was achieved at a flow rate of 1.5 mL / min over a total run time of 8 minutes.
[0153] Paclitaxel Weight Loading Analysis - Weight loading was determined by comparing a standard curve of paclitaxel to drug product of known concentration by HPLC analysis. Standards were prepared by dissolving paclitaxel in acetonitrile at concentrations of 10, 25, 50, 100, and 200 μg / mL. Paclitaxel drug product samples were prepared by dissolving this material in the mobile phase at a concentration of 1 mg / mL. The amount of paclitaxel in the drug product was then converted to a weight percentage of the total based on the known amount of drug product (i.e., 1 mg / mL).
[0154] Weight Loading Analysis of SN-38 - Weight loading was determined by comparing a standard curve of SN-38 to known concentrations of drug product by HPLC analysis. Standards were prepared by dissolving SN-38 in a 7:3 (v / v) mixture of acetonitrile and DMSO at concentrations of 50, 100, 200, 300 and 400 μg / mL. SN-38 drug product samples were prepared by dissolving this material in a 7:3 (v / v) mixture of acetonitrile and DMSO at concentrations between 1-4 mg / mL, depending on weight loading. The amount of SN-38 in the drug product was then converted to a weight percentage of the total based on the known amount of drug product.
[0155] Cabazitaxel Weight Loading Analysis - Weight loading was determined by comparing a standard curve of cabazitaxel to drug product of known concentration by HPLC analysis. Standards were prepared by dissolving cabazitaxel in acetonitrile at concentrations of 20, 40, 60, 80, and 100 μg / mL. Cabazitaxel drug product samples were prepared by dissolving this material in the mobile phase at a concentration of 1 mg / mL. The amount of cabazitaxel in the drug product was then converted to a weight percentage of the total based on the known amount of drug product (i.e., 1 mg / mL).
[0156] Docetaxel Weight Loading Analysis - Weight loading was determined by comparing a standard curve of docetaxel to known concentrations of drug product by HPLC analysis. Standards were prepared by dissolving docetaxel in acetonitrile at concentrations of 10, 50, and 100 μg / mL. Docetaxel drug product samples were prepared by dissolving this material in the mobile phase at a concentration of 1 mg / mL. The amount of docetaxel in the drug product was then converted to a weight percentage of the total based on the known amount of drug product (i.e., 1 mg / mL).
[0157] Paclitaxel Pharmacokinetics in Rats - For this study, Hilltop Lab Sprague-Dawley rats (3 males and 3 females per test article) procured from Animals were used by WuXi AppTec. TYN-21 paclitaxel formulation (100 mg of 13 wt% paclitaxel) was reconstituted in saline (5.2 mL) to yield a solution with a paclitaxel concentration of 2.50 mg / mL. Abraxane was reconstituted with 20 mL of saline according to the package insert to yield a solution of 5 mg / mL paclitaxel, and this solution was diluted 1:1 (v / v) with saline to yield a solution with a paclitaxel concentration of 2.5 mg / mL. Both TYN-21 and Abraxane solutions were administered by rapid bolus IV infusion at 2.0 mL / kg via the tail vein over 1-2 minutes to deliver a paclitaxel dose of 5.0 mg / kg. At the end of infusion (EOI), 1 h, 2 h, 4 h, and 8 h later, blood samples (approximately 300 μL) were collected from the jugular vein and administered K 2 Blood samples were collected into BD Microtainer tubes containing EDTA. Within 30 minutes of collection, blood samples were centrifuged at 3000 g for 5 minutes at 4°C. Plasma was collected into polypropylene tubes or 96-well plates, quickly frozen on dry ice, and stored at -70±10°C until LC-MS / MS analysis. Quantitation was determined by comparing a standard curve of paclitaxel in plasma (six non-zero concentrations) to samples from each time point. Abraxane was 4,648±1,306 ng * The C of paclitaxel from Abraxane was demonstrated to be 1.2 h / mL. max The mean plasma concentration of paclitaxel in TYN-21 was 20,067 ± 8,069 ng / mL. The half-life of paclitaxel from Abraxane was 3.1 ± 0.6 hours. The clearance of paclitaxel from Abraxane was 18.4 ± 5.3 mL / min / kg. TYN-21 was 5,873 ± 2,103 ng / mL. * The C of paclitaxel from TYN-21 was demonstrated to be 1.2 h / mL. maxThe mean plasma concentration of paclitaxel in TYN-21 was 18,367±7,410 ng / mL. The half-life of paclitaxel from TYN-21 was 3.2±0.4 hours. The clearance of paclitaxel from TYN-21 was 15.3±4.6 mL / min / kg. Pharmacokinetic data are shown in Figure 1. Example 1 Sar 175 -bp-[D-Leu 35 -co-L-Tyr 25 Preparation of (TFS-1)
[0158] A jacketed round bottom flask equipped with a circulating isopropanol / water bath was charged with N,N-dimethylformamide (100 mL). The bath temperature was set to 20° C. and after stirring and equilibrating for approximately 15 minutes, a solution of neopentylamine (3.31 mL of 300 mM in DMF, 86.6 mg, 1 equiv.) was added followed by sarcosine N-carboxyanhydride (20.0 g, 173.8 mmol, 175 equiv.). The funnel and sides of the reaction vessel were rinsed with additional DMF (approx. 5 mL). The reaction vessel was wrapped in aluminum foil to block light. As the reaction proceeds, the color changes from clear and colorless to a clear light orange solution. IR was used to follow the peaks at approximately 1850 and 1778 cm. -1 The progress of the reaction was monitored by the disappearance of the carbonyl stretch at 37° C. After 8 hours the reaction was >95% complete but was left overnight (another 12 hours). The bath temperature was set to 25° C. and the reaction was then charged with D-leucine N-carboxyanhydride (5.46 g, 34.77 mmol, 35 equiv.) and L-tyrosine N-carboxyanhydride (5.15 g, 24.84 mmol, 25 equiv.). The consumption of the two NCAs was observed at approximately 1851 and 1785 cm. -1Reaction was again monitored by disappearance of the carbonyl stretch in the IR at 37 °C and was complete after approximately 24 h. To aid, the reaction mixture was transferred to a beaker with the aid of a small amount of DMF (approximately 5-10 mL). With vigorous stirring using an overhead stirrer, ethyl acetate (480 mL, approximately 4 volumes) was added slowly over 1-2 min. The precipitation was rapid with a distinct solid beginning to form after addition of <1 volume of EtOAc. The precipitate was stirred for 5-10 min to help mechanically break apart any large solids and to help squeeze out any DMF that may have become trapped in the solids. Stirring was stopped and the material was allowed to settle before being collected by vacuum filtration in a medium porosity fritted glass funnel. The semi-dry material was briefly slurried on the frit with an additional 2 volumes (240 mL) of EtOAc. The product was dried in a vacuum oven at 90-100° C. for 2 days to give 19.8 g (97%) of the title compound as a fine, off-white, dense powder. 1 H NMR (DMSO-d 6 ) δ 9.2-9.0 (30H), 8.6-7.8 (48H), 7.2-6.5 (125H), 4.7-3.7 (845H), 3.0-2.6 (1440H), 1.9-1.2 (104H), 1.0-0.5 (289H);GPC(DMF, 50mM LiBr)Mn=17.6kDa, Mp=18.7kDa, PDI=1.08. Example 2 Sar 175 -bp-[D-Leu 30 -co-L-Tyr 20 Preparation of (TFS-2)
[0159] After cooling a jacketed round-bottom flask equipped with a circulating isopropanol / water bath to 20 °C, sarcosine N-carboxyanhydride (19.9 g, 172.9 mmol, 175 equiv.) was added followed by N,N-dimethylformamide (100 mL). The mixture was stirred for <30 s, after which neopentylamine (3.30 mL of 300 mM in DMF, 86.2 mg, 1 equiv.) was added. The reaction vessel was wrapped in aluminum foil to prevent exposure to light. After 15-20 min, the reaction began to change from the initial clear and colorless solution to a bright orange color that continued to deepen as the reaction proceeded. IR was used to measure the chromaticity at approximately 1850 and 1778 cm. -1 The progress of the reaction was monitored by the disappearance of the NCA carbonyl stretch of Sar (1778 cm -1 (Is the preferred wavelength for monitoring). The reaction was about 90% complete after 6 hours but was left to stir overnight. The reaction was complete the next day after a total of 19 hours. The circulating bath temperature was raised to 25°C, after which D-leucine N-carboxyanhydride (4.66 g, 29.66 mmol, 30 equiv.) and L-tyrosine N-carboxyanhydride (4.10 g, 19.78 mmol, 20 equiv.) were added. Additional DMF (approximately 5 mL) was used to rinse the funnel and sides of the reaction vessel. Shortly after the reaction started, significant CO 2 Gas formation was observed. Using IR, peaks at approximately 1851 and 1785 cm -1 The progress of the reaction was monitored by the disappearance of the carbonyl stretch of the NCA of D-Leu and the NCA of L-Tyr (1785 cm -1is the preferred wavelength for monitoring). As the reaction progressed, the color changed from a clear light orange to a clear yellow-orange solution, which was only evident after several hours. After 10 hours the reaction was >85% complete, and after 24 hours it was >99.9% complete. The reaction mixture (approximately 125 mL total) was transferred to a beaker and fitted with an overhead stirrer. With vigorous stirring, ethyl acetate (250 mL, 2 volumes) was added to precipitate the product. The solid was collected by filtration into a medium fritted glass funnel. The solid was transferred back to the original precipitation beaker with additional EtOAc (250 mL) and slurried with vigorous stirring for 20 minutes. The solid was collected in a new fritted glass funnel, and then the same 20 minute slurrying procedure was repeated one more time with EtOAc (250 mL). The product was dried on a frit in a vacuum oven at 90-100° C. to give 15.95 g (84.1%) of the title compound as a fine, off-white, dense powder. 1 H NMR (DMSO-d 6 ) δ 9.2-8.9 (21H), 8.6-7.6 (39H), 7.2-6.4 (100H), 4.7-3.7 (694H), 3.1-2.6 (1039H), 1.9 (3H), 1.7-1.2 (33H), 1.0-0.6 (186H); GPC (DMF, 50mM LiBr) Mn=16.9kDa, Mp=18.0kDa, PDI=1.08. Example 3 Sar 175 -bp-[D-Leu 30 -co-L-Tyr 20 Preparation of ]-Ac (TFS-2-Ac)
[0160] A round bottom flask was charged with TFS-2 (500 mg, 0.0261 mmol, 1 equiv) and N,N-dimethylformamide (5.0 mL) and the mixture was stirred and heated with a heat gun to dissolve the material. Once the reaction mixture was cooled to ambient temperature, triethylamine (36 μL, 0.261 mmol, 10 equiv) and acetic anhydride (25 μL, 0.261 mmol, 10 equiv) were added. The reaction was stirred for 24 h and then transferred to a beaker using a minimal amount of N,N-dimethylformamide (approximately 1.5 mL) to aid in the transfer. With vigorous stirring, a large excess of ethyl acetate (40 mL) was added over 1 min. The precipitate was stirred for 5 min and the solid was then collected in a fritted glass funnel. The product on the funnel was washed with additional ethyl acetate (2×40 mL) and then dried at 95° C. for 48 hours to give the title compound as a granular white powder (320 mg, 64.0%). 1 H NMR (DMSO-d 6 ) δ 9.2-9.0 (16H), 8.8-7.5 (54H), 7.5-6.4 (100H), 4.7-3.7 (843H), 3.2-2.6 (1272H), 2.2 (24H), 1.8-1.0 (96H), 1.0-0.4 (211H). Example 4 Sar 125 -bp-[D-Glu(OBn) 15 -co-L-Glu(OBn) 15 Preparation of
[0161] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (30 mg, 1 eq.), NCA of sarcosine (4.95 g, 125 eq.), NCA of D-Glu(OBn) (1.36 g, 15 eq.) and L-Glu(OBn) (1.36 g, 15 eq.). This gave the title compound as a pale yellow solid (4.6 g, 86%). GPC (DMF, 50 mM LiBr) Mn=13.9 kDa, Mp=14.9 kDa, PDI=1.15. Example 5 Sar 125 -bp-[D-Glu(OBn) 20-co-L-Glu(OBn) 20 Preparation of
[0162] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (30 mg, 1 eq.), NCA of sarcosine (4.95 g, 125 eq.), NCA of D-Glu(OBn) (1.81 g, 20 eq.) and L-Glu(OBn) (1.81 g, 20 eq.). This gave the title compound as a pale yellow solid (4.9 g, 80%). GPC (DMF, 50 mM LiBr) Mn=14.6 kDa, Mp=15.6 kDa, PDI=1.11. Example 6 Sar 125 -bp-[D-Phe 15 -co-L-Tyr 15 Preparation of
[0163] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (30 mg, 1 eq.), NCA of sarcosine (4.95 g, 125 eq.), NCA of D-Phe (0.987 g, 15 eq.) and L-Tyr (1.07 g, 15 eq.). This gave the title compound as a pale yellow solid (3.9 g, 83%). GPC (DMF, 50 mM LiBr) Mn=13.7 kDa, Mp=14.5 kDa, PDI=1.03. Example 7 Sar 125 -bp-[D-Leu 20 -co-L-Tyr 15 Preparation of
[0164] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (30 mg, 1 eq.), NCA of sarcosine (4.95 g, 125 eq.), NCA of D-Leu (1.08 g, 20 eq.) and L-Tyr (1.07 g, 15 eq.). This gave the title compound as a pale yellow solid (3.7 g, 79%). GPC (DMF, 50 mM LiBr) Mn=15.1 kDa, Mp=16.1 kDa, PDI=1.09. Example 8 Sar 175 -bp-[D-Glu(OBn)25 -co-L-Glu(OBn) 25 Preparation of
[0165] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (43 mg, 1 eq.), NCA of sarcosine (10.0 g, 175 eq.), NCA of D-Glu(OBn) (3.27 g, 25 eq.) and L-Glu(OBn) (3.27 g, 25 eq.). This gave the title compound as a pale yellow solid (10 g, 86%). GPC (DMF, 50 mM LiBr) Mn=15.9 kDa, Mp=16.9 kDa, PDI=1.06. Example 9 Sar 175 -bp-[D-Phe 20 -co-L-Tyr 20 Preparation of
[0166] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (43 mg, 1 eq.), NCA of sarcosine (10.0 g, 175 eq.), NCA of D-Phe (1.90 g, 20 eq.) and L-Tyr (2.06 g, 20 eq.). This gave the title compound as a pale yellow solid (7.8 g, 85%). GPC (DMF, 50 mM LiBr) Mn=14.9 kDa, Mp=15.9 kDa, PDI=1.04. Example 10 Sar 175 -bp-[Sar 10 -co-L-Tyr 50 Preparation of
[0167] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (43 mg, 1 eq.), sarcosine NCA (first block, 10.0 g, 175 eq.), sarcosine NCA (0.57 g, 10 eq.) and L-Tyr (5.14 g, 50 eq.). This gave the title compound as a light yellow solid (10.1 g, 96%). GPC (DMF, 50 mM LiBr) Mn=15.5 kDa, Mp=16.4 kDa, PDI=1.15. Example 11 Sar 175-bp-[D-Phe 25 -co-L-Glu(OBn) 25 Preparation of
[0168] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (21.7 mg, 1 eq.), NCA of sarcosine (4.98 g, 175 eq.), NCA of D-Phe (1.19 g, 25 eq.) and L-Glu(OBn) (1.64 g, 25 eq.). This gave the title compound as a pale yellow solid (3.8 g, 71%). GPC (DMF, 50 mM LiBr) Mn=16.3 kDa, Mp=17.4 kDa, PDI=1.09. Example 12 Sar 175 -bp-[D-Phe 30 -co-L-Tyr 10 Preparation of
[0169] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (21.7 mg, 1 eq.), NCA of sarcosine (4.98 g, 175 eq.), NCA of D-Phe (1.43 g, 30 eq.) and L-Tyr (0.515 g, 10 eq.). This gave the title compound as a pale yellow solid (4.26 g, 92.4%). GPC (DMF, 50 mM LiBr) Mn=15.9 kDa, Mp=16.9 kDa, PDI=1.60. (Example 13) Sar 175 -bp-[D-Phe 10 -co-L-Tyr 30 Preparation of
[0170] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (21.7 mg, 1 eq.), NCA of sarcosine (4.98 g, 175 eq.), NCA of D-Phe (0.475 g, 10 eq.) and L-Tyr (1.54 g, 30 eq.). This gave the title compound as a pale yellow solid (4.66 g, 99.3%). GPC (DMF, 50 mM LiBr) Mn=16.1 kDa, Mp=17.1 kDa, PDI=1.07. Example 14 Sar 175 -bp-[D-Phe 25 -co-L-Tyr 15 Preparation of
[0171] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (21.7 mg, 1 eq.), NCA of sarcosine (5.0 g, 175 eq.), NCA of D-Phe (1.19 g, 25 eq.) and L-Tyr (0.772 g, 15 eq.). This gave the title compound as a pale yellow solid (4.37 g, 94.3%). GPC (DMF, 50 mM LiBr) Mn=14.1 kDa, Mp=15.0 kDa, PDI=1.54. Example 15 Sar 175 -bp-[D-Phe 15 -co-L-Tyr 25 Preparation of
[0172] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (21.7 mg, 1 eq.), NCA of sarcosine (5.0 g, 175 eq.), NCA of D-Phe (0.712 g, 15 eq.) and L-Tyr (1.29 g, 25 eq.). This gave the title compound as a pale yellow solid (4.57 g, 97.7%). GPC (DMF, 50 mM LiBr) Mn=14.4 kDa, Mp=15.3 kDa, PDI=1.07. Example 16 Sar 210 -bp-[D-Phe 15 -co-L-Tyr 25 Preparation of
[0173] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (18 mg, 1 eq.), NCA of sarcosine (5.0 g, 210 eq.), NCA of D-Phe (0.593 g, 15 eq.) and L-Tyr (1.07 g, 25 eq.). This gave the title compound as a pale yellow solid (3.43 g, 78.0%). GPC (DMF, 50 mM LiBr) Mn=17.0 kDa, Mp=18.1 kDa, PDI=1.06. (Example 17) Sar 210 -bp-[D-Phe 10 -co-L-Tyr 30 Preparation of
[0174] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (18 mg, 1 eq.), NCA of sarcosine (5.0 g, 210 eq.), NCA of D-Phe (0.396 g, 10 eq.) and L-Tyr (1.29 g, 30 eq.). This gave the title compound as a pale yellow solid (3.62 g, 82.0%). GPC (DMF, 50 mM LiBr) Mn=17.0 kDa, Mp=18.1 kDa, PDI=1.08. (Example 18) Sar 210 -bp-[D-Phe 5 -co-L-Tyr 35 Preparation of
[0175] The general procedure of Example 1 was followed with the following equivalents and amounts of reagents: neopentylamine (18 mg, 1 eq.), NCA of sarcosine (5.0 g, 210 eq.), NCA of D-Phe (0.198 g, 5 eq.) and L-Tyr (1.50 g, 35 eq.). This gave the title compound as a pale yellow solid (3.64 g, 82.2%). GPC (DMF, 50 mM LiBr)Mn=16.8kDa, Mp=17.8kDa, PDI=1.13. (Example 19) Sar 235 -bp-[D-Phe 10 -co-L-Tyr 30 Preparation of (TFS-3)
[0176] After cooling a jacketed round-bottom flask equipped with a circulating isopropanol / water bath to 20 °C, sarcosine N-carboxyanhydride (15.0 g, 130.5 mmol, 235 equiv.) was added followed by N,N-dimethylformamide (75 mL). The mixture was stirred for <30 s, after which neopentylamine (1.85 mL of 300 mM in DMF, 48.4 mg, 0.555 mmol, 1 equiv.) was added. The reaction vessel was wrapped in aluminum foil to prevent exposure to light. After 15-20 min, the reaction began to change from the initial clear and colorless solution to a bright orange color that continued to deepen as the reaction proceeded. IR was used to measure the chromaticity at approximately 1850 and 1778 cm. -1 The progress of the reaction was monitored by the disappearance of the NCA carbonyl stretch of Sar (1778 cm -1 is the preferred wavelength for monitoring). The reaction was complete the next day after a total of 22 hours. The circulating bath temperature was raised to 25°C, after which D-phenylalanine N-carboxyanhydride (1.06 g, 5.55 mmol, 10 equiv.) and L-tyrosine N-carboxyanhydride (3.45 g, 16.7 mmol, 30 equiv.) were added. Additional DMF (approximately 5 mL) was used to rinse the funnel and sides of the reaction vessel. Shortly after the reaction started, significant CO 2 Gas formation was observed. Using IR, the peaks at approximately 1847 and 1786 cm -1 The progress of the reaction was monitored by the disappearance of the NCA carbonyl stretch of D-Phe and L-Tyr (1786 cm -1is the preferred wavelength for monitoring). As the reaction progressed, the color changed from a clear light orange to a clear yellow-orange solution that was only evident after several hours. The reaction was complete after a total of 30 hours. The reaction mixture (approximately 100 mL total) was transferred to a beaker and attached to an overhead stirrer. With vigorous stirring, ethyl acetate (400 mL, 4 volumes) was added to precipitate the product. The solid was collected by filtration into a medium fritted glass funnel, and the semi-dry material was then transferred back to the original precipitation beaker with additional EtOAc (200 mL, 2 volumes) and stirred vigorously for 20 minutes to form a slurry. The solid was collected in the same glass funnel and washed once more with additional EtOAc (100 mL, 1 volume). The product was dried in a vacuum oven at 90-100 °C for 2 days to give 11.3 g (87.9%) of the title compound as a fine off-white powder. 1 H NMR (DMSO-d 6 ) δ 9.3-9.0 (28H), 8.5-7.8 (45H), 7.4-6.4 (170H), 4.6-3.6 (784H), 3.2-2.5 (1326H), 1.9 (5H), 1.2-1.1 (6H), 0.9-0.8 (14H); GPC (DMF, 50mM LiBr) Mn=18.1kDa, Mp=19.3kDa, PDI=1.07. (Example 20) Sar 235 -bp-[D-Phe 15 -co-L-Tyr 25 Preparation of
[0177] The general procedure of Example 19 was followed with the following equivalents and amounts of reagents: neopentylamine (16.1 mg, 1 eq.), NCA of sarcosine (5.0 g, 235 eq.), NCA of D-Phe (0.531 g, 15 eq.) and L-Tyr (0.959 g, 25 eq.). This gave the title compound as a cream solid (3.24 g, 75.9%). GPC (DMF, 50 mM LiBr) Mn=17.1 kDa, Mp=18.2 kDa, PDI=1.07. Example 21 Sar 235-bp-[D-Phe 5 -co-L-Tyr 35 Preparation of
[0178] The general procedure of Example 19 was followed with the following equivalents and amounts of reagents: neopentylamine (16.1 mg, 1 eq.), NCA of sarcosine (5.0 g, 235 eq.), NCA of D-Phe (0.177 g, 5 eq.) and L-Tyr (1.34 g, 35 eq.). This gave the title compound as a cream solid (3.89 g, 90.5%). GPC (DMF, 50 mM LiBr) Mn=17.0 kDa, Mp=18.1 kDa, PDI=1.10. Example 22 30% paclitaxel feed containing TFS-2
[0179] 2.0 g of TFS-2 (Poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 )) and 2.0 g of trehalose were dissolved in 90 mL of 30:70 (v / v) tert-butanol:water to produce a solution of 22.2 mg / mL of each component. The pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH. Separately, paclitaxel (603 mg) was dissolved in 30 mL of tert-butanol using an ultrasonic water bath to produce a solution of 20.1 mg / mL. The two solutions were mixed and stirred for 15 minutes, and then filtered through a 0.22 μm PVDF filter. This formulation solution was then transferred to 20 mL vials in aliquots of 10 mL per vial, frozen at −80° C., and then lyophilized for 2 days. This resulted in 4.2 g of shredded white cake containing 12.9% weight loading of paclitaxel. (Example 23) 15% paclitaxel feed containing TFS-2
[0180] 100 mg of TFS-2 (Poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20)) and 100 mg of trehalose were dissolved in 10 mL of 40:60 (v / v) tert-butanol:water to produce a 10 mg / mL solution of each component. The pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH. Separately, paclitaxel (15 mg) was dissolved in 0.75 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes, and then filtered through a 0.22 μm PVDF filter. The formulation solution was frozen at −80° C. and then lyophilized for 2 days. This gave the drug product as a shredded white cake containing 7.51% weight loading of paclitaxel. Example 24 15% paclitaxel feed containing TFS-1
[0181] The copolymer used was TFS-1 (poly(Sar) 175 -block-poly(d-Leu 35 -co-Tyr 25 The general method of Example 23 was used, except that: 1)) was used. This gave the drug product as a shredded white cake containing 6.90% weight loading of paclitaxel. (Example 25) 20% paclitaxel feed containing TFS-2
[0182] The general method of Example 23 is used, except that the drug solution consists of 20 mg of paclitaxel dissolved in 1.0 mL of tert-butanol, which yields the drug product as a shredded white cake containing 9.33% weight loading of paclitaxel. (Example 26) 20% paclitaxel feed containing TFS-1
[0183] The copolymer used was TFS-1 (poly(Sar) 175 -block-poly(d-Leu 35 -co-Tyr 25The general method of Example 23 is used, except that the drug solution consists of 20 mg of paclitaxel dissolved in 1.0 mL of tert-butanol, which gives the drug product as a shredded white cake containing 9.20% weight loading of paclitaxel. Example 27 25% paclitaxel feed containing TFS-2
[0184] 50 mg of TFS-2 (Poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 )) and 50 mg of trehalose were dissolved in 5 mL of 40:60 (v / v) tert-butanol:water to produce a 10 mg / mL solution of each component. The pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH. Separately, paclitaxel (12.5 mg) was dissolved in 0.625 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes, and then filtered through a 0.22 μm PVDF filter. The formulation solution was frozen at −80° C. and then lyophilized for 2 days. This gave the drug product as a shredded white cake containing 11.4% weight loading of paclitaxel. (Example 28) 30% paclitaxel feed containing TFS-2
[0185] The general method of Example 27 is used, except that the drug solution consists of 15 mg of paclitaxel dissolved in 0.75 mL of tert-butanol, which gives the drug product as a shredded white cake containing 14.6% weight loading of paclitaxel. (Example 29) 25% paclitaxel feed (4mg / mL) containing TFS-2
[0186] 100 mg of TFS-2 (Poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20)) and 100 mg of trehalose were dissolved in 5 mL of 35:65 (v / v) tert-butanol:water to produce a 20 mg / mL solution of each component. The pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH. Separately, paclitaxel (25 mg) was dissolved in 1.25 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes to produce a solution with a paclitaxel concentration of 4 mg / mL, which was then filtered through a 0.22 μm PVDF filter. The formulation solution was frozen at −80° C. and then lyophilized for 2 days. This resulted in the drug product as a shredded white cake containing 9.9% weight loading of paclitaxel. (Example 30) 30% paclitaxel feed (4mg / mL) containing TFS-2
[0187] 100 mg of TFS-2 (Poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 The general method of Example 29 is used, except that 100 mg of trehalose and 100 mg of trehalose were dissolved in 6 mL of 35:65 (v / v) tert-butanol:water to produce a solution of 16.7 mg / mL of each component, and the drug solution consisted of 30 mg of paclitaxel dissolved in 1.5 mL of tert-butanol. This gave the drug product as a shredded white cake containing 11.7% weight loading of paclitaxel. (Example 31) 35% paclitaxel feed (4mg / mL) containing TFS-2
[0188] 100 mg of TFS-2 (Poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20The general method of Example 29 is used, except that 100 mg of trehalose and 100 mg of glycerol were dissolved in 7 mL of 35:65 (v / v) tert-butanol:water to produce a solution of 14.3 mg / mL of each component, and the drug solution consisted of 35 mg of paclitaxel dissolved in 1.75 mL of tert-butanol. This gave the drug product as a shredded white cake containing 14.3% weight loading of paclitaxel. Example 32 25% paclitaxel feed (5mg / mL) containing TFS-2
[0189] 100 mg of TFS-2 (Poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 )) and 100 mg of trehalose were dissolved in 3.75 mL of 35:65 (v / v) tert-butanol:water to produce a solution of 26.7 mg / mL of each component. The pH of the resulting solution was adjusted to pH 7.0 using 25 mM NaOH. Separately, paclitaxel (25 mg) was dissolved in 1.25 mL of tert-butanol using an ultrasonic water bath to produce a solution of 20 mg / mL. The two solutions were mixed and stirred for 15 minutes to produce a solution with a paclitaxel concentration of 5 mg / mL, which was then filtered through a 0.22 μm PVDF filter. The formulation solution was frozen at −80° C. and then lyophilized for 2 days. This resulted in the drug product as a shredded white cake containing 10.2% weight loading of paclitaxel. (Example 33) 30% paclitaxel feed (5mg / mL) containing TFS-2
[0190] 100 mg of TFS-2 (Poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20The general method of Example 32 is used, except that 100 mg of trehalose and 100 mg of trehalose were dissolved in 4.5 mL of 35:65 (v / v) tert-butanol:water to produce a solution of 22.2 mg / mL of each component, and the drug solution consisted of 30 mg of paclitaxel dissolved in 1.5 mL of tert-butanol. This gave the drug product as a shredded white cake containing 11.5% weight loading of paclitaxel. (Example 34) 35% paclitaxel feed (5mg / mL) containing TFS-2
[0191] 100 mg of TFS-2 (Poly(Sar) 175 -block-poly(d-Leu 30 -co-Tyr 20 The general method of Example 32 is used, except that 100 mg of trehalose and 100 mg of trehalose were dissolved in 5.25 mL of 35:65 (v / v) tert-butanol:water to produce a solution of 19.0 mg / mL of each component, and the drug solution consisted of 35 mg of paclitaxel dissolved in 1.75 mL of tert-butanol. This gave the drug product as a shredded white cake containing 13.1% weight loading of paclitaxel. (Example 35) Sar 125 -bp-[D-Glu(OBn) 15 -co-L-Glu(OBn) 15 ], no cryoprotectant, 2.5% paclitaxel feed
[0192] 200mg Poly(Sar) 125 -block-poly[(d-Glu(OBn) 15 -co-L-Glu(OBn) 15
[0036] was dissolved in 10 mL of 40:60 (v / v) tert-butanol:water to produce a 20 mg / mL solution of the polymer. Separately, paclitaxel (5 mg) was dissolved in 0.25 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes, then filtered through a 0.22 μm PVDF filter. The formulation solution was frozen at −80° C. and then lyophilized for 2 days. This gave the drug product as a white solid containing 3.0% weight loading of paclitaxel. (Example 36) Sar 125 -bp-[D-Glu(OBn) 15 -co-L-Glu(OBn) 15 ], no cryoprotectant, 5.0% paclitaxel feed
[0193] The general method of Example 35 was used, except that the drug substance solution consisted of 10 mg of paclitaxel dissolved in 0.5 mL of tert-butanol, which was added to the polymer solution, yielding the drug product as a white solid containing 6.3% weight loading of paclitaxel. (Example 37) Sar 125 -bp-[D-Glu(OBn) 15 -co-L-Glu(OBn) 15 ], no cryoprotectant, 10.0% paclitaxel feed
[0194] The general method of Example 35 was used, except that the drug substance solution consisted of 20 mg of paclitaxel dissolved in 1.0 mL of tert-butanol, which was added to the polymer solution, yielding the drug product as a white solid containing 11.1% weight loading of paclitaxel. (Example 38) Sar 125 -bp-[D-Glu(OBn) 15 -co-L-Glu(OBn) 15 ], 2.5% paclitaxel feed
[0195] 100mg Poly(Sar) 125 -block-poly[d-Glu(OBn) 15 -co-L-Glu(OBn) 15 ] and 100 mg of trehalose were dissolved in 5 mL of 40:60 (v / v) tert-butanol:water to produce a 20 mg / mL solution of each component. Separately, paclitaxel (2.5 mg) was dissolved in 0.125 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes, then filtered through a 0.22 μm PVDF filter. The formulation solution was frozen at −80° C. and then lyophilized for 2 days. This gave the drug product as a shredded white cake containing 1.6% weight loading of paclitaxel. (Example 39) Sar 125 -bp-[D-Glu(OBn) 15 -co-L-Glu(OBn) 15 ] containing 5% paclitaxel feed
[0196] The general method of Example 38 was used, except that the drug substance solution consisted of 5.0 mg of paclitaxel dissolved in 0.25 mL of tert-butanol, which was added to the polymer and trehalose solution, yielding the drug product as a white solid containing 1.9% weight loading of paclitaxel. (Example 40) Sar 125 -bp-[D-Glu(OBn) 15 -co-L-Glu(OBn) 15 ], 10% paclitaxel feed
[0197] The general method of Example 38 was used, except that the drug substance solution consisted of 10.0 mg of paclitaxel dissolved in 0.5 mL of tert-butanol, which was added to the polymer and trehalose solution, yielding the drug product as a white solid containing 4.1% weight loading of paclitaxel. (Example 41) Sar 125 -bp-[D-Glu(OBn) 20 -co-L-Glu(OBn) 20 ], no cryoprotectant, 2.5% paclitaxel feed
[0198] 200mg Poly(Sar) 125 -block-poly[d-Glu(OBn) 20 -co-L-Glu(OBn) 20
[0036] was dissolved in 10 mL of 40:60 (v / v) tert-butanol:water to produce a 20 mg / mL solution of the polymer. Separately, paclitaxel (5 mg) was dissolved in 0.25 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes, then filtered through a 0.22 μm PVDF filter. The formulation solution was frozen at −80° C. and then lyophilized for 2 days. This gave the drug product as a white solid containing 2.7% weight loading of paclitaxel. (Example 42) Sar 125 -bp-[D-Glu(OBn) 20 -co-L-Glu(OBn) 20 ], no cryoprotectant, 5.0% paclitaxel feed
[0199] The general method of Example 41 was used, except that the drug substance solution consisted of 10 mg of paclitaxel dissolved in 0.5 mL of tert-butanol, which was added to the polymer solution, yielding the drug product as a white solid containing 5.1% weight loading of paclitaxel. (Example 43) Sar 125 -bp-[D-Glu(OBn) 20 -co-L-Glu(OBn) 20 ], no cryoprotectant, 10.0% paclitaxel feed
[0200] The general method of Example 41 was used, except that the drug substance solution consisted of 20 mg of paclitaxel dissolved in 1.0 mL of tert-butanol, which was added to the polymer solution, yielding the drug product as a white solid containing 8.3% weight loading of paclitaxel. (Example 44) Sar 125 -bp-[D-Glu(OBn) 20 -co-L-Glu(OBn) 20 ], 2.5% paclitaxel feed
[0201] 100mg Poly(Sar) 125 -block-poly[d-Glu(OBn) 20 -co-L-Glu(OBn) 20 ] and 100 mg of trehalose were dissolved in 5 mL of 40:60 (v / v) tert-butanol:water to produce a 20 mg / mL solution of each component. Separately, paclitaxel (2.5 mg) was dissolved in 0.125 mL of tert-butanol using an ultrasonic water bath to produce a 20 mg / mL solution. The two solutions were mixed and stirred for 15 minutes, then filtered through a 0.22 μm PVDF filter. The formulation solution was frozen at −80° C. and then lyophilized for 2 days. This gave the drug product as a shredded white cake containing 1.4% weight loading of paclitaxel. (Example 45) Sar 125 -bp-[D-Glu(OBn) 20 -co-L-Glu(OBn) 20 ], 5% paclitaxel feed
[0202] The general method of Example 44 was used, except that the drug substance solution consisted of 5.0 mg of paclitaxel dissolved in 0.25 mL of tert-butanol, which was added to the polymer and trehalose solution, yielding the drug product as a white solid containing 2.5% weight loading of paclitaxel. (Example 46) Sar 125-bp-[D-Glu(OBn) 20 -co-L-Glu(OBn) 20 ], 10% paclitaxel feed
[0203] The general method of Example 44 was used, except that the drug substance solution consisted of 10.0 mg of paclitaxel dissolved in 0.5 mL of tert-butanol, which was added to the polymer and trehalose solution, yielding the drug product as a white solid containing 4.3% weight loading of paclitaxel. (Example 47) Contains TFS-3, 15% SN-38 feed
[0204] Trehalose (8.0 g) was dissolved in 400 mL of water, and then 2.0 g of TFS-3 (Sar 235 [D-Phe 10 -co-Tyr 30 ]) was added to produce a solution of 20 mg / mL trehalose and 5 mg / mL TFS-3. The resulting solution was stirred for 1 hour and then filtered through a 0.5 μm polypropylene filter. Separately, a solution of SN-38 was prepared by dissolving 281 mg in 3.75 mL DMSO with the aid of heat to produce a stock solution of 75 mg / mL. The SN-38 stock solution was added while shear mixing 375 mL of the polymer / trehalose solution with a homogenizer at 10,000 RPM and mixing was continued for 1 minute. The resulting homogenous emulsion was processed with an inlet pressure of 100 PSI and an operating pressure of approximately 25,000 PSI through a microfluidizer, an auxiliary processing chamber, and then twice through a 50 μm X-interaction chamber with an outlet tube cooled in an ice-water bath. The emulsion was then filtered through an mPES hollow fiber filter (10 kDa MWCO, 790 cm 2 The extrusion solution was diafiltered against 2.5 L of 20 mg / mL trehalose at a flow rate of 300 mL / min using a tangential flow filtration system with a 20 cm diameter diafiltration column and a surface area of 1.5 mm. The solution was then concentrated to approximately ¼ of its original volume to give a final polymer concentration of approximately 20 mg / mL. The formulation solution was then filtered using a 20 cm diameter diafiltration column. 2The solution was filtered through a 0.2 μm PES filter with a surface area of 1.0 μm. The filtered solution was frozen at −80° C. and lyophilized for 2 days, yielding the drug formulation as a shredded, slightly yellow cake with a weight loading of 5.73% SN-38. (Example 48) 20% SN-38 feed containing TFS-3
[0205] The general method of Example 47 was used, except that a total of 5.0 mL of SN-38 solution (75 mg / mL) was homogenized with 375 mL of the polymer / trehalose solution. This yielded the drug product as a shredded, slightly yellow cake with a 7.54% SN-38 weight loading. (Example 49) 25% SN-38 feed containing TFS-3
[0206] The general method of Example 47 was used, except that a total of 6.25 mL of SN-38 solution (75 mg / mL) was homogenized with 375 mL of the polymer / trehalose solution. This yielded the drug product as a shredded, slightly yellow cake with a 9.35% SN-38 weight loading. (Example 50) 30% SN-38 feed containing TFS-3
[0207] The general method of Example 47 was used, except that a total of 7.5 mL of SN-38 solution (75 mg / mL) was homogenized with 375 mL of the polymer / trehalose solution. This yielded the drug product as a shredded, slightly yellow cake with an SN-38 weight loading of 11.64%. (Example 51) 40% SN-38 feed including TFS-3
[0208] The general method of Example 47 was used, except that a total of 10.0 mL of SN-38 solution (75 mg / mL) was homogenized with 375 mL of the polymer / trehalose solution. This yielded the drug product as a shredded yellow cake with a weight loading of 14.80% SN-38. (Example 52) Sar 175 -bp-[D-Phe 25 -co-L-Glu(OBn) 25 ], 10% SN-38 feed
[0209] Trehalose (750 mg) was dissolved in 150 mL of water, and then 750 mg of Sar 175 -bp-[D-Phe 25 -co-L-Glu(OBn) 25 ] was added to produce a 5 mg / mL solution of each component. Separately, a solution of SN-38 was prepared by dissolving 75 mg in 1.0 mL of DMSO using heat to produce a 75 mg / mL stock solution. The SN-38 stock solution was added while shear mixing the polymer / trehalose solution with a homogenizer at 10,000 RPM, and mixing was continued for 1 minute. The resulting homogenous emulsion was processed with an inlet pressure of 100 PSI and an operating pressure of approximately 25,000 PSI through a microfluidizer, an auxiliary processing chamber, and then a 50 μm X-interaction chamber with an outlet tubing cooled in an ice-water bath. It was then passed through an mPES hollow fiber filter (10 kDa MWCO, 790 cm 2 The extrusion solution was diafiltered against 1.2 L of 5 mg / mL trehalose using a tangential flow filtration system with a surface area of 1.2 mm at 25° C. at a flow rate of 300 mL / min. Half of the formulation solution was frozen at −80° C. and lyophilized for 2 days. The other half of the formulation was filtered through a 0.2 μm PES filter, frozen at −80° C., and lyophilized for 2 days. This yielded the drug formulation as a shredded, slightly yellow cake with an SN-38 weight loading of 2.8% for the unfiltered formulation and 0.3% for the filtered formulation. (Example 53) Sar175 -bp-[D-Phe 10 -co-L-Tyr 30 ], 10% SN-38 feed
[0210] The polymer used was Sar 175 -bp-[D-Phe 10 -co-L-Tyr 30 The general method of Example 52 was used, except that: 1.0 mL of 100 mL of 100% SN-38 was added to the filtered formulation. This resulted in the drug formulations being obtained as shredded, slightly yellow cakes with SN-38 weight loadings of 4.2% for the unfiltered formulations and 4.1% for the filtered formulations. (Example 54) Sar 175 -bp-[D-Phe 25 -co-L-Tyr 15 ], 10% SN-38 feed
[0211] The polymer used was Sar 175 -bp-[D-Phe 25 -co-L-Tyr 15 The general method of Example 52 was used, except that: 1.0 mL of 100 mL of 100% SN-38 was added to the filtered formulation. This resulted in the drug formulations being obtained as shredded, slightly yellow cakes with SN-38 weight loadings of 4.1% for the unfiltered formulations and 0.5% for the filtered formulations. (Example 55) Sar 175 -bp-[D-Phe 15 -co-L-Tyr 25 ], 10% SN-38 feed
[0212] The polymer used was Sar 175 -bp-[D-Phe 15 -co-L-Tyr 25 The general method of Example 52 was used, except that: 1.0 mL of 100 mL of 100% SN-38 was added to the filtered formulation. This resulted in the drug formulations being obtained as shredded, slightly yellow cakes with SN-38 weight loadings of 3.9% for the unfiltered formulations and 2.8% for the filtered formulations. (Example 56) Sar 210 -bp-[D-Phe 15 -co-L-Tyr 25 ], 15% SN-38 feed
[0213] Trehalose (1.0 g) was dissolved in 200 mL of water, followed by 1.0 g of Sar 210 -bp-[D-Phe 15 -co-L-Tyr 25 ] was added to produce a 5 mg / mL solution of each component. Separately, a solution of SN-38 was prepared by dissolving 150 mg in 2.0 mL of DMSO using heat to produce a 75 mg / mL stock solution. The SN-38 stock solution was added while shear mixing the polymer / trehalose solution with a homogenizer at 10,000 RPM, and mixing was continued for 1 minute. The resulting homogenous emulsion was processed with an inlet pressure of 100 PSI and an operating pressure of approximately 25,000 PSI through a microfluidizer, an auxiliary processing chamber, and then a 50 μm X-interaction chamber with an outlet tubing cooled in an ice-water bath. The emulsion was then passed through an mPES hollow fiber filter (10 kDa MWCO, 790 cm 2 Approximately 120 mL of the extrusion solution was diafiltered against 600 mL of 5 mg / mL trehalose at a flow rate of 300 mL / min using a tangential flow filtration system with a 1000 rpm sieve (surface area of 1000 μm). The formulation was filtered through a 0.45 μm PVDF filter, then through a 0.2 μm PES filter, frozen at −80° C., and lyophilized for 2 days. This yielded the drug formulation as a fragmented, slightly yellow cake with a weight loading of 5.0% SN-38. (Example 57) Sar 175 -bp-[D-Phe 10 -co-L-Tyr 30 ], 15% SN-38 feed
[0214] The polymer used was Sar 175 -bp-[D-Phe 10 -co-L-Tyr 30The general method of Example 56 was used, except that: [0.15% SN-38 weight loading] was used. This yielded the drug formulation as a shredded, slightly yellow cake with a 4.9% SN-38 weight loading. (Example 58) Sar 175 -bp-[D-Phe 5 -co-L-Tyr 35 ], 15% SN-38 feed
[0215] The polymer used was Sar 175 -bp-[D-Phe 5 -co-L-Tyr 35 The general method of Example 56 was used, except that: [0.15% by weight] was used. This afforded the drug formulation as a shredded, slightly yellow cake with a weight loading of 2.9% SN-38. (Example 59) Sar 210 -bp-[D-Phe 15 -co-L-Tyr 25 ], 10% SN-38 feed
[0216] Trehalose (1.0 g) was dissolved in 200 mL of water, followed by 1.0 g of Sar 210 -bp-[D-Phe 15 -co-L-Tyr 25 ] was added to produce a solution of 5 mg / mL of each component. To aid in dissolution, the polymer / trehalose solution was heated to 65°C for approximately 30 minutes. Separately, a solution of SN-38 was prepared using heat by dissolving 100 mg in 1.33 mL of DMSO to produce a stock solution of 75 mg / mL. The SN-38 stock solution was added while shear mixing the polymer / trehalose solution with a homogenizer at 10,000 RPM, and mixing was continued for 1 minute. The resulting homogenous emulsion was processed with an inlet pressure of 100 PSI and an operating pressure of approximately 25,000 PSI through a microfluidizer, an auxiliary processing chamber, and then a 50 μm X-interaction chamber with an outlet tubing cooled in an ice-water bath. It was then passed through an mPES hollow fiber filter (10 kDa MWCO, 790 cm 2Approximately 120 mL of the extrusion solution was diafiltered against 600 mL of 5 mg / mL trehalose at a flow rate of 300 mL / min using a tangential flow filtration system with a 1000 rpm sieve (surface area of 1000 μm). The formulation was filtered through a 0.45 μm PVDF filter, then through a 0.2 μm PES filter, frozen at −80° C., and lyophilized for 2 days. This yielded the drug formulation as a fragmented, slightly yellow cake with a SN-38 weight loading of 3.8%. (Example 60) Sar 210 -bp-[D-Phe 10 -co-L-Tyr 30 ], 10% SN-38 feed
[0217] The polymer used was Sar 210 -bp-[D-Phe 10 -co-L-Tyr 30 The general method of Example 59 was used, except that: [0.15% by weight of SN-38 was added to the mixture.] This afforded the drug formulation as a shredded, slightly yellow cake with a weight loading of 3.4% SN-38. (Example 61) Sar 210 -bp-[D-Phe 15 -co-L-Tyr 25 ], 15% SN-38 feed
[0218] Trehalose (1.0 g) was dissolved in 200 mL of water, followed by 1.0 g of Sar 210 -bp-[D-Phe 15 -co-L-Tyr 25] was added to produce a solution of 5 mg / mL of each component. To aid in dissolution, the polymer / trehalose solution was stirred overnight and then filtered through a 0.2 μm PES filter. Separately, a solution of SN-38 was prepared by dissolving 150 mg in 2.0 mL of DMSO using heat to produce a stock solution of 75 mg / mL. The SN-38 stock solution was added while shear mixing the polymer / trehalose solution with a homogenizer at 10,000 RPM, and mixing was continued for 1 minute. The resulting homogenous emulsion was processed through a microfluidizer, an auxiliary processing chamber, and then a 50 μm X-interaction chamber with an outlet tubing cooled in an ice-water bath, with an inlet pressure of 100 PSI and an operating pressure of approximately 25,000 PSI. It was then filtered through an mPES hollow fiber filter (10 kDa MWCO, 790 cm 2 Approximately 120 mL of the extrusion solution was diafiltered against 600 mL of 5 mg / mL trehalose at a flow rate of 300 mL / min using a tangential flow filtration system with a 1.0 mm diameter 10 ... (Example 62) Sar 210 -bp-[D-Phe 10 -co-L-Tyr 30 ], 15% SN-38 feed
[0219] The polymer used was Sar 210 -bp-[D-Phe 10 -co-L-Tyr 30 The general method of Example 61 was used, except that: [0.15% SN-38 weight loading] was used. This yielded the drug formulation as a shredded, slightly yellow cake with a 3.0% SN-38 weight loading. (Example 63) Sar 235 -bp-[D-Phe 15 -co-L-Tyr 25], 15% SN-38 feed
[0220] The polymer used was Sar 235 -bp-[D-Phe 15 -co-L-Tyr 25 The general method of Example 61 was used, except that: [0.15% SN-38 weight loading] was used. This yielded the drug formulation as a shredded, slightly yellow cake with a weight loading of 1.6% SN-38. (Example 64) TFS-3(Sar 235 -bp-[D-Phe 10 -co-L-Tyr 30 ]) containing 15% SN-38 feed
[0221] The polymer used was TFS-3 (Sar 235 -bp-[D-Phe 10 -co-L-Tyr 30 The general method of Example 61 was used, except that the SN-38 weight loading was 3.7%. This yielded the drug formulation as a shredded, slightly yellow cake with a SN-38 weight loading of 3.7%. (Example 65) Sar 235 -bp-[D-Phe 15 -co-L-Tyr 25 ], 6% SN-38 feed
[0222] Trehalose (1.0 g) was dissolved in 200 mL of water, followed by 1.0 g of Sar 235 -bp-[D-Phe 15 -co-L-Tyr 25] was added to produce a solution of 5 mg / mL of each component. To aid in dissolution, the polymer / trehalose solution was stirred overnight and then filtered through a 0.8 / 0.45 μm PES filter. Separately, a solution of SN-38 was prepared by dissolving 45 mg in 0.6 mL of DMSO using heat to produce a stock solution of 75 mg / mL. The SN-38 stock solution was added while shear mixing 150 mL of the filtered polymer / trehalose solution using a homogenizer at 10,000 RPM, and mixing was continued for 1 minute. The resulting homogenous emulsion was processed through a microfluidizer, an auxiliary processing chamber, and then a 50 μm X-interaction chamber with an outlet tubing cooled in an ice-water bath at an inlet pressure of 100 PSI and an operating pressure of approximately 25,000 PSI. It was then filtered through an mPES hollow fiber filter (10 kDa MWCO, 790 cm 2 Approximately 120 mL of the extrusion solution was diafiltered against 600 mL of 5 mg / mL trehalose at a flow rate of 300 mL / min using a tangential flow filtration system with a 1000 rpm sieve (surface area of 100 μm). The formulation was filtered through a 0.45 μm PVDF filter, then through a 0.2 μm PES filter, frozen at −80° C., and lyophilized for 2 days. This yielded the drug formulation as a shredded, slightly yellow cake with a SN-38 weight loading of 2.02%. (Example 66) Sar 235 -bp-[D-Phe 15 -co-L-Tyr 25 ], 8% SN-38 feed
[0223] The general method of Example 65 is used, except that the SN-38 solution consisted of 60 mg dissolved in 0.8 mL of DMSO. This yielded the drug formulation as a shredded, slightly yellow cake with a weight loading of 2.49% SN-38. (Example 67) TFS-3(Sar 235 -bp-[D-Phe 10 -co-L-Tyr 30 ]) containing 6% SN-38 feed
[0224] The polymer used was TFS-3 (Sar 235 -bp-[D-Phe 10 -co-L-Tyr 30 The general method of Example 65 was used, except that the SN-38 weight loading was 2.35%. This afforded the drug formulation as a shredded, slightly yellow cake with a SN-38 weight loading of 2.35%. (Example 68) TFS-3(Sar 235 -bp-[D-Phe 10 -co-L-Tyr 30 ]) containing 8% SN-38 feed
[0225] The polymer used was TFS-3 (Sar 235 -bp-[D-Phe 10 -co-L-Tyr 30 ]) and the general method of Example 65 is used, except that the SN-38 solution consisted of 60 mg dissolved in 0.8 mL DMSO. This afforded the drug formulation as a fragmented, slightly yellow cake with a weight loading of 2.88% SN-38. (Example 69) (Sar 125 -bp-[D-Phe 20 -co-L-Tyr 15 ]) containing 15% cabazitaxel feed
[0226] 100mg Poly(Sar) 125 -block-poly(d-Leu 20 -co-Tyr 15) and 100 mg of trehalose were dissolved in 10 mL of 40:60 (v / v) tert-butanol:water to produce a 10 mg / mL solution of each component. Separately, cabazitaxel (15 mg) was dissolved in 1.65 mL of 13% (v / v) DMSO in tert-butanol using an ultrasonic water bath to produce a 9 mg / mL solution. The two solutions were mixed and stirred for 15 minutes, then filtered through a 0.22 μm PVDF filter. The formulation solution was frozen at −80° C. and then lyophilized for 2 days. This gave the drug product as a shredded white cake containing 1.82% weight loading of cabazitaxel. (Example 70) (Sar 175 -bp-[D-Glu(OBn) 25 -co-L-Glu(OBn) 15 ]) containing 15% cabazitaxel feed
[0227] The polymer used was poly(Sar). 175 -block-poly(d-Glu(OBn) 25 -co-L-Glu(OBn) 25 The general method of Example 69 was used, except that 2.22% weight loading of cabazitaxel was used. This gave the drug product as a shredded white cake. (Example 71) TFS-2(Sar 175 -bp-[D-Leu 30 -co-L-Tyr 20 ]) containing 15% cabazitaxel feed
[0228] The polymer used was TFS-2 (poly(Sar) 175 -block-poly(D-Leu 30 -co-L-Tyr 20 The general method of Example 69 was used, except that: 1) was added 1.00% by weight of Cabazitaxel to obtain the drug product as a shredded white cake containing 2.00% by weight loading of Cabazitaxel. (Example 72) TFS-1(Sar 175-bp-[D-Leu 35 -co-L-Tyr 25 ]) containing 15% cabazitaxel feed
[0229] The polymer used was TFS-1 (poly(Sar) 175 -block-poly(D-Leu 35 -co-L-Tyr 25 The general method of Example 69 was used, except that: 1)) was used. This afforded the drug product as a shredded white cake containing 1.84% weight loading of cabazitaxel. (Example 73) TFS-2(Sar 175 -bp-[D-Leu 30 -co-L-Tyr 20 ]) containing 10% cabazitaxel feed
[0230] Add 200 mg of TFS-2 (Poly(Sar)) to a beaker equipped with a magnetic stir bar. 175 -block-poly(d-Leu 30 -co-Tyr 20 )) was taken and dissolved in 100 mL of DI water. Separately, cabazitaxel (20 mg) was dissolved in 2 mL of dichloromethane. The aqueous solution was vigorously stirred and the organic phase was added dropwise over approximately 1 minute. The solution was stirred overnight to allow dichloromethane to evaporate. The resulting solution was vacuum filtered through a μm PVDF filter, frozen at −80° C., and then lyophilized for 2 days. This afforded the drug product as a shredded white cake containing 0.77% weight loading of cabazitaxel. (Example 74) TFS-1(Sar 175 -bp-[D-Leu 35 -co-L-Tyr 25 ]) containing 10% cabazitaxel feed
[0231] The polymer used was TFS-1 (poly(Sar) 175 -block-poly(D-Leu 35 -co-L-Tyr 25The general method of Example 73 was used, except that: 1)) was used. This afforded the drug product as a shredded white cake containing 1.04% weight loading of cabazitaxel. (Example 75) (Sar 125 -bp-[D-Leu 20 -co-L-Tyr 15 ]) containing 5% docetaxel feed
[0232] 100mg Poly(Sar) 125 -block-poly(d-Leu 20 -co-Tyr 15 ) and 100 mg of trehalose were dissolved in 10 mL of 40:60 (v / v) tert-butanol:water to yield a 10 mg / mL solution of each component. Separately, docetaxel (5 mg) was dissolved in 0.25 mL of tert-butanol using an ultrasonic water bath to yield a 20 mg / mL solution. The two solutions were mixed, stirred for 15 minutes, frozen at -80°C, and then lyophilized for two days. This yielded the drug product as a shredded white cake containing 2.36% weight loading of docetaxel. (Example 76) (Sar 125 -bp-[D-Leu 20 -co-L-Tyr 15 ]) containing 10% docetaxel feed
[0233] The general method of Example 75 was used, except that the drug solution was prepared by dissolving docetaxel (10 mg) in 0.5 mL of tert-butanol, which gave the drug product as a shredded white cake containing 4.76% weight loading of docetaxel. (Example 77) (Sar 125 -bp-[D-Leu 20 -co-L-Tyr 15 ]) containing 15% docetaxel feed
[0234] The general method of Example 75 was used, except that the drug solution was prepared by dissolving docetaxel (10 mg) in 0.5 mL of tert-butanol, which gave the drug product as a shredded white cake containing 6.98% weight loading of docetaxel. The present invention provides, for example, the following items. (Item 1) Formula I: [ka] A multi-block copolymer of the formula: R 1a is H or an optionally substituted aliphatic group, R 1b is H or an optionally substituted aliphatic group, R 2 is H, an optionally substituted aliphatic group, or an optionally substituted CO-(C1-C6) aliphatic group; R y are each independently a D-amino acid side chain; R z are each independently an L-amino acid side chain; x is 125 to 350; y is between 5 and 35; z is 5 to 35; Multiblock copolymer. (Item 2) R y are each independently the side chain of γ-benzyl-D-glutamic acid, D-leucine, D-tyrosine, D-phenylalanine, D-alanine, D-valine, D-isoleucine, D-norleucine, O-acetyl-D-tyrosine, O-benzyl-D-tyrosine or ε-benzyl-D-lysine; R zis each independently a side chain of γ-benzyl-L-glutamic acid, L-leucine, L-tyrosine, L-phenylalanine, L-alanine, L-valine, L-isoleucine, L-norleucine, O-acetyl-L-tyrosine, O-benzyl-L-tyrosine or ε-benzyl-L-lysine. (Item 3) R y are each independently the side chain of γ-benzyl-D-glutamic acid, D-leucine, D-tyrosine, or D-phenylalanine; R z is each independently a side chain of γ-benzyl-L-glutamic acid, L-leucine, L-tyrosine, or L-phenylalanine. (Item 4) R y are the side chains of D-leucine, R z Each of the multi-block copolymers according to item 1 is a side chain of L-tyrosine. (Item 5) R 1a But H, R 1b is a benzyl group, a methoxybenzyl group, a neopentyl group, or a hexyl group, R 2 is H or COCH 3 5. The multi-block copolymer according to any one of items 1 to 4, (Item 6) The following structure: [ka] A multi-block copolymer having the formula: (Item 7) The following structure: [ka] A multi-block copolymer having the formula: (Item 8) The following structure: [ka] A multi-block copolymer having the formula: (Item 9) The following structure: [ka] A multi-block copolymer having the formula: (Item 10) The following structure: [ka] A multi-block copolymer having the formula: (Item 11) The following structure: [ka] Multiblock copolymer by. (Item 12) 12. A composition comprising the multiblock copolymer according to any one of items 1 to 11 and one or more hydrophobic molecules. (Item 13) Item 13. The composition according to item 12, wherein the hydrophobic molecule is present in an amount of about 1% to about 25% by weight of the composition. (Item 14) 14. The composition according to item 12 or 13, wherein the hydrophobic molecule is paclitaxel, docetaxel, cabazitaxel or SN-38, or a pharma- ceutically acceptable salt of these compounds. (Item 15) 15. The composition according to any one of items 12 to 14, further comprising a cryoprotectant. (Item 16) 16. The composition of claim 15, wherein the cryoprotectant is glycine, polyvinylpyrrolidine, polyethylene glycol, mannitol, sorbitol, sucrose, glucose, raffinose, sucralose, lactose, trehalose, dextran or dextrose. (Item 17) 17. The composition of claim 16, wherein the cryoprotectant is trehalose. (Item 18) 19. The composition according to any one of items 12 to 18, in the form of a lyophilized powder. (Item 19) 19. The composition according to any one of items 12 to 18, further comprising a pharma- ceutically acceptable vehicle. (Item 20) 20. The composition according to item 19, wherein the vehicle is selected from water, 1,3-butanediol, Ringer's solution or isotonic sodium chloride solution. (Item 21) 12. A method for increasing the solubility of a hydrophobic molecule in an aqueous solution, comprising encapsulating said hydrophobic molecule in a multi-block copolymer according to any one of items 1 to 11. (Item 22) a. providing the multi-block copolymer in an aqueous solution; b. providing said hydrophobic molecules in an organic solution; c. mixing the aqueous solution and the organic solution to form an emulsion; d. harvesting the supernatant from the emulsion; e. producing a dry powder from the supernatant; and f. solubilizing the dry powder 22. The method according to claim 21, comprising: (Item 23) 23. The method of claim 22, wherein the aqueous solution and the organic solution are mixed using a homogenizer. (Item 24) 24. The method of claim 22 or 23, wherein the emulsion is processed using a microfluidizer to produce an extrusion solution. (Item 25) 25. The method of claim 24, further comprising filtering the extrusion solution and collecting the supernatant. (Item 26) 26. The method of any one of items 22 to 25, wherein a cryoprotectant is added to the aqueous solution, the supernatant, or both. (Item 27) 27. The method of claim 26, wherein the cryoprotectant is glycine, polyvinylpyrrolidine, polyethylene glycol, mannitol, sorbitol, sucrose, glucose, raffinose, sucralose, lactose, trehalose, dextran or dextrose. (Item 28) 27. The method according to any one of items 22 to 26, wherein the dry powder is produced by lyophilization. (Item 29) 30. The method according to any one of items 21 to 29, wherein the hydrophobic molecule is paclitaxel, docetaxel, cabazitaxel or SN-38, or a pharma- ceutically acceptable salt of these compounds. (Item 30) a) dissolving a hydrophobic molecule, a copolymer of formula I, and optionally a cryoprotectant in aqueous tert-butanol, thereby forming a mixed solution; and b) freeze-drying the mixture, if necessary 19. A method for preparing a composition according to any one of items 12 to 18, comprising: (Item 31) a) dissolving a hydrophobic molecule in tert-butanol, thereby forming a hydrophobic molecule solution; b) dissolving the copolymer of formula I, and optionally a cryoprotectant, in aqueous tert-butanol, thereby forming a copolymer solution; c) mixing the hydrophobic molecule solution with the copolymer solution, thereby forming a mixed solution; and d) freeze-drying the mixture, if necessary. 19. A method for preparing a composition according to any one of items 12 to 18, comprising: (Item 32) a) dissolving a hydrophobic molecule in tert-butanol, thereby forming a paclitaxel solution; b) dissolving the copolymer of formula I, and optionally a cryoprotectant, in aqueous tert-butanol, thereby forming a copolymer solution; c) mixing the solution of hydrophobic molecules with the copolymer solution, thereby forming a mixed solution; d) filtering the mixed solution, thereby forming a filtered solution; e) optionally lyophilizing the filtered solution. 19. A method for preparing a composition according to any one of items 12 to 18, comprising: (Item 33) a. dissolving a hydrophobic molecule, a copolymer of formula I, and optionally a cryoprotectant in an aqueous solution, thereby forming a mixed solution; b. treating the mixed solution with a high shear mixer, thereby forming a high shear mixer solution; and c. optionally lyophilizing the high shear mixer solution. 19. A method for preparing a composition according to any one of items 12 to 18, comprising: (Item 34) a. dissolving a hydrophobic molecule in an organic solvent, thereby forming a hydrophobic molecule solution; b. dissolving the copolymer of formula I, and optionally a cryoprotectant, in an aqueous solution, thereby forming a copolymer solution; c. mixing the hydrophobic molecule solution with the copolymer solution, thereby forming a mixed solution; d. treating the mixed solution with a high shear mixer, thereby forming a high shear mixer solution; and e. optionally lyophilizing said high shear mixer solution. 19. A method for preparing a composition according to any one of items 12 to 18, comprising: (Item 35) a. dissolving a hydrophobic molecule in an organic solvent, thereby forming a hydrophobic molecule solution; b. dissolving the copolymer of formula I, and optionally a cryoprotectant, in an aqueous solution, thereby forming a copolymer solution; c. mixing the hydrophobic molecule solution with the copolymer solution, thereby forming a mixed solution; d. treating the mixed solution with a high shear mixer, thereby forming a high shear mixer solution; e. treating said high shear mixer solution with a diafiltration system, thereby forming a diafiltered solution; f. filtering the diafiltered solution, thereby forming a filtered solution; and g. optionally lyophilizing the filtered solution. 19. A method for preparing a composition according to any one of items 12 to 18, comprising:
Claims
[Claim 1] The invention described in the specification.
Citation Information
Patent Citations
Metal ion-containing amphiphilic block polymer and metal ion-containing nanoparticle, and molecule imaging probe using the nanoparticle and agent deliver system
JP2014105161A
Polymeric micelles for polynucleotide encapsulation
WO2010127159A2
Ligand-drug-conjugate comprising a single molecular weight polysarcosine
WO2019081455A1
